{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":1298,"total_is_capped":false,"direct_labels_cover":1,"predictions_cover":1298,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"7311300f78e4","filters":{"topic":"Neuroendocrine Tumor Research Advances"}},"results":[{"id":"W2158474413","doi":"10.1056/nejmoa1003825","title":"Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":2547,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Sunitinib; Sunitinib malate; Neuroendocrine tumors; Tyrosine-kinase inhibitor; Medicine; Cancer research; Tyrosine kinase; Internal medicine; Pancreatic neuroendocrine tumor; Oncology; Receptor; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.07397403406338811,"gpt":0.3392087866342718,"spread":0.2652347525708837,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002681101,0.0001854913,0.0007103464,0.000225292,0.00004939676,0.000003329077,0.0001850162,0.000004555259,0.000390252],"category_scores_gemma":[0.0008681663,0.00008661392,0.0001643071,0.0001918722,0.0002343265,0.00007093971,0.00001310185,0.0001927674,0.000002122776],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003538109,"about_ca_system_score_gemma":0.0001682751,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001807927,"about_ca_topic_score_gemma":0.00002110764,"domain_scores_codex":[0.9982859,0.00008729215,0.0006879453,0.0001266354,0.0004892263,0.0003230128],"domain_scores_gemma":[0.9976495,0.0009789063,0.0004163992,0.0002901809,0.0003118359,0.0003531971],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.05411963,0.003134123,0.09825055,0.0009926494,0.002366531,0.04545827,0.007239545,0.00007960566,0.03280184,0.002309485,0.01612153,0.7371262],"study_design_scores_gemma":[0.2552135,0.1305834,0.0556183,0.001481412,0.003019326,0.09710946,0.001817294,0.0002208623,0.07303636,0.00435417,0.3772321,0.0003138406],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9821431,0.004205516,0.0002373915,0.01034932,0.0004558266,0.0007833226,0.000006335212,0.00001448585,0.001804707],"genre_scores_gemma":[0.9897425,0.005144058,0.0008968186,0.0002461796,0.001952057,0.000006957391,0.000002883697,0.00003117561,0.001977423],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7368124,"threshold_uncertainty_score":0.4272986,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2209368665","doi":"10.1016/s0140-6736(15)00817-x","title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":1264,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Everolimus; Placebo; Medicine; Gastrointestinal tract; Internal medicine; Lung; Neuroendocrine tumors; Oncology; Gastroenterology; Pathology; Alternative medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.05816962875443518,"gpt":0.3631413652564144,"spread":0.3049717365019792,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004576331,0.0002890425,0.001100913,0.00007181636,0.0001560895,0.00001839825,0.0004854981,0.000003891362,0.00005072671],"category_scores_gemma":[0.001731197,0.0001111108,0.0003495462,0.0002564974,0.0002711914,0.00008535641,0.00005464793,0.000241425,0.000004060012],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001004005,"about_ca_system_score_gemma":0.0003753087,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007383189,"about_ca_topic_score_gemma":0.00006000062,"domain_scores_codex":[0.9976022,0.0002855949,0.0005493385,0.0003023656,0.0006960029,0.0005644974],"domain_scores_gemma":[0.9958143,0.002499298,0.0003592573,0.0009448131,0.0002121304,0.0001701615],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.941479,0.006232519,0.0304595,0.0001169578,0.0003482251,0.0009282852,0.0005762749,0.003059682,0.002331621,0.00002871792,0.01191221,0.002527021],"study_design_scores_gemma":[0.9287694,0.0243013,0.01972923,0.0001610863,0.001175422,0.005885927,0.00303849,0.00747245,0.004057519,0.0001114715,0.005111313,0.0001864376],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9802762,0.000758673,0.0001849411,0.007485111,0.0002922509,0.01060131,0.00009849651,0.0000336755,0.0002693342],"genre_scores_gemma":[0.9956582,0.0001406407,0.0002605223,0.0001763668,0.0006558393,0.001441844,0.000006271496,0.00003990365,0.001620459],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01806878,"threshold_uncertainty_score":0.4530967,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2888018398","doi":"10.1038/s41379-018-0110-y","title":"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","year":2018,"lang":"en","type":"article","venue":"Modern Pathology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":1125,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; University Health Network","funders":"National Cancer Institute; Centre International de Recherche sur le Cancer; World Health Organization","keywords":"Pathology; Neuroendocrine tumors; Confusion; Cancer; Medicine; Psychology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1566008095620603,"gpt":0.490781157698686,"spread":0.3341803481366257,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003682173,0.0001787461,0.0003344718,0.0004480483,0.0003573525,0.0000447416,0.000208404,0.00002231932,0.00005361996],"category_scores_gemma":[0.001525558,0.0001633303,0.00003350233,0.0003411313,0.0004687647,0.00009935787,0.00009421623,0.0004026883,0.000007464013],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00018956,"about_ca_system_score_gemma":0.0003649793,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006920295,"about_ca_topic_score_gemma":0.0005628007,"domain_scores_codex":[0.9975415,0.0003312572,0.0003565011,0.0007342848,0.0003865434,0.0006498713],"domain_scores_gemma":[0.997651,0.0006535256,0.000132139,0.0004514988,0.0008606047,0.000251184],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.02291643,0.003904683,0.1119748,0.001336509,0.000235577,0.002316478,0.007515993,0.0001007158,0.1220051,0.2514306,0.03178547,0.4444776],"study_design_scores_gemma":[0.0239532,0.05504798,0.2094016,0.00137118,0.0001151051,0.009310649,0.001638085,0.1727134,0.1097963,0.2923357,0.122641,0.00167578],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9031636,0.0002205377,0.01577714,0.07661124,0.0006017967,0.003160477,0.0001476184,0.0001346926,0.0001829594],"genre_scores_gemma":[0.9759934,0.0003626135,0.01845179,0.0025403,0.0007883049,0.0007319494,0.000160768,0.00008755529,0.0008833486],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4428018,"threshold_uncertainty_score":0.6660416,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2589112207","doi":"10.1038/nature21063","title":"Whole-genome landscape of pancreatic neuroendocrine tumours","year":2017,"lang":"en","type":"article","venue":"Nature","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":1010,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pancreas Centre (Canada)","funders":"Medical Research Council; Academy of Medical Sciences; Cancer Research UK; Wellcome Trust; Pancreatic Cancer UK","keywords":"Biology; MUTYH; Genetics; Gene; Germline mutation; Germline; DNA repair; DNA glycosylase; Chromatin; Cancer research; Mutation","retraction":null,"screen_n_in":null,"score":{"opus":0.01511527606550634,"gpt":0.3263789575968915,"spread":0.3112636815313852,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005693709,0.000157552,0.0003812171,0.0001309912,0.0001349541,0.00003699349,0.0004177754,0.00003157648,0.000162908],"category_scores_gemma":[0.001216245,0.0001227611,0.0001082078,0.00009519622,0.000151148,0.0001597727,0.0001656078,0.001804288,0.00005484729],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001545371,"about_ca_system_score_gemma":0.00007055941,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001409135,"about_ca_topic_score_gemma":0.00001161856,"domain_scores_codex":[0.998614,0.00003077061,0.000188208,0.0002870249,0.0004995638,0.0003804022],"domain_scores_gemma":[0.9984362,0.0000638298,0.0001611731,0.000991351,0.0001512363,0.0001962652],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001602395,0.0005980319,0.565244,0.001230326,0.0001800195,0.0326172,0.00005672416,0.00001511903,0.3725951,0.001170374,0.02151532,0.003175378],"study_design_scores_gemma":[0.003126622,0.0007978036,0.864431,0.0001535013,0.0001121388,0.003575783,0.00006069382,0.00004605304,0.03028021,0.0003698143,0.09685261,0.0001937408],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9698492,0.002041996,0.000001349044,0.01165052,0.0002116386,0.0003858966,0.00006030327,0.0000607874,0.01573826],"genre_scores_gemma":[0.9925666,0.0001906357,0.0002524036,0.0004752227,0.0002158882,0.00001188803,0.00003262454,0.0000328345,0.006221894],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3423149,"threshold_uncertainty_score":0.7838833,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4220660991","doi":"10.1007/s12022-022-09708-2","title":"Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms","year":2022,"lang":"en","type":"review","venue":"Endocrine Pathology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":957,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Neuroendocrine tumors; Neuroendocrine differentiation; Grading (engineering); Chromogranin A; MEN1; Biology; Pathology; Synaptophysin; Somatostatin receptor; Somatostatin; Hormone; Endocrine system; Medicine; Immunohistochemistry; Neuroscience; Internal medicine; Endocrinology; Cancer; Prostate cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1308989411007658,"gpt":0.4156465789728535,"spread":0.2847476378720876,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002432453,0.000610713,0.003422986,0.000614082,0.0001109909,0.000006657733,0.001112104,0.00002223773,0.002167146],"category_scores_gemma":[0.001717517,0.0004225626,0.001266218,0.001623065,0.0005374425,0.00007212784,0.001351466,0.001722859,0.00003045509],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001511916,"about_ca_system_score_gemma":0.0007019369,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002535789,"about_ca_topic_score_gemma":0.00001327564,"domain_scores_codex":[0.9941817,0.001488142,0.00169916,0.0008772897,0.001003551,0.0007501405],"domain_scores_gemma":[0.9952053,0.0008222602,0.001475791,0.002187453,0.0001440958,0.000165145],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001497457,0.0007829393,0.0005322066,0.06118705,0.00029185,0.01081026,0.00002657024,0.000002081922,0.0003644006,0.004452083,0.005933261,0.9154676],"study_design_scores_gemma":[0.0007440708,0.0007392245,0.0003783881,0.001934168,0.0007930917,0.03438431,0.00002670159,0.000004543615,0.0002776633,0.00008930296,0.9604113,0.0002172416],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0006147119,0.9921381,0.0000023788,0.0005514305,0.0008964007,0.002300034,0.0002881075,0.00005737148,0.003151488],"genre_scores_gemma":[0.0002358307,0.9935303,0.00009893483,0.000115607,0.0001307923,0.0005701685,0.0001737643,0.0001425818,0.005001971],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.954478,"threshold_uncertainty_score":0.9998226,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1575433014","doi":"10.1002/cncr.29099","title":"Exploring the rising incidence of neuroendocrine tumors: A population‐based analysis of epidemiology, metastatic presentation, and outcomes","year":2014,"lang":"en","type":"article","venue":"Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":855,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"Health Sciences Centre; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"Ontario Institute for Cancer Research","keywords":"Medicine; Incidence (geometry); Epidemiology; Population; Retrospective cohort study; Cohort; Neuroendocrine tumors; Cohort study; Presentation (obstetrics); Internal medicine; Pediatrics; Demography; Surgery; Environmental health","retraction":null,"screen_n_in":null,"score":{"opus":0.1351138466823844,"gpt":0.4237649881002987,"spread":0.2886511414179143,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003348187,0.000106606,0.0006180116,0.0003287107,0.00004660719,0.000004191836,0.0001060678,0.000001571171,0.00004472267],"category_scores_gemma":[0.004726131,0.00006856993,0.0001128359,0.0007478769,0.0001750043,0.0001569954,0.00005285726,0.0001170388,3.952889e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002593953,"about_ca_system_score_gemma":0.00003802298,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001905962,"about_ca_topic_score_gemma":0.0002911606,"domain_scores_codex":[0.9984915,0.0003319152,0.000488248,0.0002232365,0.0002500284,0.0002150646],"domain_scores_gemma":[0.9970064,0.002137858,0.0002805946,0.0003472932,0.0001445146,0.00008337617],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00006310496,0.00002288478,0.9887821,0.0001657311,0.0002162815,0.00001658356,0.00004128708,0.006856561,0.0006770072,0.0002597304,0.00001760294,0.002881125],"study_design_scores_gemma":[0.0004649254,0.00009484986,0.9824296,0.0000711356,0.0006416541,0.00001622272,0.00006631209,0.01238916,0.003412786,0.0002508771,0.0001135927,0.00004885189],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995638,0.0003963981,0.0007380096,0.00286536,0.00004354055,0.0002671259,0.0000134781,0.00001528505,0.00002278825],"genre_scores_gemma":[0.9980198,0.0001496153,0.001267196,0.0003789052,0.00002071528,0.00009313753,0.00001138095,0.00001162742,0.0000475782],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006352465,"threshold_uncertainty_score":0.5657962,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2065387828","doi":"10.1097/mpa.0b013e3181ebb168","title":"NANETS Treatment Guidelines","year":2010,"lang":"en","type":"article","venue":"Pancreas","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":571,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"National Cancer Institute; National Institutes of Health","keywords":"Pancreas; Stomach; Neuroendocrine tumors; Medicine; Consensus conference; Internal medicine; General surgery; Gastroenterology; Intensive care medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.05620690148065747,"gpt":0.396871322834314,"spread":0.3406644213536565,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005451731,0.0001151705,0.000194826,0.00006208791,0.00004266114,0.00001264566,0.0000682321,0.00000672491,0.0006072396],"category_scores_gemma":[0.0006086488,0.00007949966,0.00006551968,0.00009311349,0.00005831902,0.00004854371,0.00002436373,0.0001433066,0.0004430061],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002359411,"about_ca_system_score_gemma":0.00009523766,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003632939,"about_ca_topic_score_gemma":0.0001737046,"domain_scores_codex":[0.9991027,0.0000154792,0.0001560943,0.0002083538,0.000229378,0.0002880597],"domain_scores_gemma":[0.9991698,0.00005871257,0.00002695401,0.0003673365,0.0001341675,0.0002430664],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005960517,0.0006713094,0.1236237,0.00007745522,0.0001317206,0.008153698,0.00005113846,0.000002179047,0.6867051,0.001733691,0.02645177,0.1518022],"study_design_scores_gemma":[0.00166752,0.0006353821,0.02259142,0.0000209883,0.00004363924,0.003854919,0.00002176301,0.00007397273,0.09329649,0.0003278075,0.8773484,0.0001176523],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9727752,0.0003063328,0.000004444643,0.004607799,0.0002254388,0.0003045939,0.000006031744,0.0001280016,0.02164215],"genre_scores_gemma":[0.9811859,0.0002318491,0.004963979,0.0004798897,0.0005430071,0.00005524497,0.00001395787,0.00002470197,0.01250154],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8508967,"threshold_uncertainty_score":0.6648847,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2096735709","doi":"10.1038/nrc3680","title":"RET revisited: expanding the oncogenic portfolio","year":2014,"lang":"en","type":"review","venue":"Nature reviews. Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":512,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"Cancer Research Society","keywords":"Cancer research; Proto-Oncogene Proteins c-ret; Receptor tyrosine kinase; Biology; Tyrosine kinase; Kinase; Receptor; Medicine; Glial cell line-derived neurotrophic factor; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.0595424393162713,"gpt":0.4726026194114034,"spread":0.4130601800951321,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001358433,0.001009563,0.005739641,0.0003666573,0.0001981882,0.00008329035,0.001004828,0.0002467574,0.001464322],"category_scores_gemma":[0.00245462,0.0005081792,0.002173556,0.001655369,0.0001780675,0.0001197778,0.0003002415,0.00595743,0.0006356379],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000634715,"about_ca_system_score_gemma":0.0008409175,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001445845,"about_ca_topic_score_gemma":0.00001209314,"domain_scores_codex":[0.9942164,0.0009318737,0.001584833,0.001164846,0.001118046,0.0009839564],"domain_scores_gemma":[0.9953609,0.0006002173,0.001243621,0.002138667,0.0002325732,0.000424026],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001191959,0.00001867095,0.000007409677,0.06168701,0.0001685968,0.0004057403,0.000003306389,2.522126e-8,0.000001100687,0.00008739223,0.1335153,0.8040935],"study_design_scores_gemma":[0.0002467481,0.00009013153,0.000001753332,0.0931619,0.002352137,0.002445923,0.000002304277,3.075745e-7,0.000004839052,0.0000217997,0.9012705,0.0004016423],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[6.807488e-7,0.9870276,0.000003999918,0.0006507227,0.0008721065,0.005570446,0.00007245506,0.0001128317,0.005689128],"genre_scores_gemma":[0.000003121767,0.9834364,0.0001448214,0.002367423,0.003392883,0.001673242,0.0001775881,0.0002166691,0.00858782],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8036919,"threshold_uncertainty_score":0.999737,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2257387609","doi":"10.1159/000443168","title":"ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms","year":2016,"lang":"en","type":"article","venue":"Neuroendocrinology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":492,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"Haukeland Universitetssjukehus; Università Cattolica del Sacro Cuore; University of Bern","keywords":"Internal medicine; Medicine; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.05660958717898139,"gpt":0.3625620032792534,"spread":0.305952416100272,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0000290558,0.000570681,0.0008810017,0.0004855452,0.0001827681,0.00003204138,0.0004688239,0.00001354976,0.000386033],"category_scores_gemma":[0.003456973,0.0003981438,0.0003450875,0.0002920055,0.0005785199,0.0001379464,0.0003291215,0.0003797143,0.0004275529],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007751752,"about_ca_system_score_gemma":0.0002378654,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001577247,"about_ca_topic_score_gemma":0.00002840743,"domain_scores_codex":[0.9949222,0.0001868679,0.0009671669,0.001313215,0.0005468011,0.002063795],"domain_scores_gemma":[0.9965409,0.0007646255,0.0002341859,0.001119297,0.0007449252,0.0005960467],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.009656182,0.000851162,0.04185787,0.0003904139,0.0003158416,0.06713454,0.000006587333,0.00005766937,0.4622309,0.009206753,0.2900907,0.1182014],"study_design_scores_gemma":[0.01032023,0.003861506,0.005042013,0.00008357053,0.0001218206,0.09052182,0.00001305514,0.0001100745,0.1588658,0.001214599,0.7294344,0.0004111057],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8032304,0.0005657063,0.0007790988,0.1895645,0.001673098,0.002135579,0.0002296358,0.0008060736,0.001015928],"genre_scores_gemma":[0.9595875,0.004649286,0.01002393,0.01020514,0.001324972,0.0006107846,0.00004339814,0.0002891383,0.01326588],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4393438,"threshold_uncertainty_score":0.9998471,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2995074379","doi":"10.1097/mpa.0000000000001454","title":"The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors","year":2019,"lang":"en","type":"article","venue":"Pancreas","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":385,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Neuroendocrine tumors; Medicine; Consensus conference; Pancreatic neuroendocrine tumor; General surgery; Oncology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.01416440742089523,"gpt":0.2812481316178185,"spread":0.2670837241969233,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002010184,0.0004441546,0.0007801161,0.00006771959,0.0002621474,0.00004808448,0.0005732829,0.000002061451,0.0001967632],"category_scores_gemma":[0.00026942,0.0002402537,0.0004338834,0.0008619867,0.0009114641,0.00005590253,0.0003297825,0.0007258111,0.0002714126],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007243862,"about_ca_system_score_gemma":0.0001113092,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002433215,"about_ca_topic_score_gemma":0.00003588004,"domain_scores_codex":[0.9959407,0.0003892204,0.0006637167,0.0006812421,0.001206332,0.001118807],"domain_scores_gemma":[0.9956222,0.002042491,0.0003299364,0.001529695,0.0001512688,0.0003244117],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01318079,0.002243182,0.7753618,0.002178582,0.002440433,0.1149427,0.0001049161,0.0002794974,0.00230931,0.02044665,0.04729411,0.01921798],"study_design_scores_gemma":[0.007476753,0.004768839,0.5952277,0.0004601984,0.0005546488,0.02470885,0.00187665,0.0009859533,0.005748552,0.0002090665,0.3572278,0.0007550223],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9742769,0.000361508,3.806237e-7,0.01416694,0.0001525606,0.001827632,0.00003183709,0.0001219633,0.009060293],"genre_scores_gemma":[0.9903938,0.001497976,0.0001174385,0.001916478,0.0001168965,0.0001730158,0.00001404236,0.00008781855,0.005682588],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3099337,"threshold_uncertainty_score":0.9797263,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1991912136","doi":"10.1038/ng.2821","title":"Somatic mutation of CDKN1B in small intestine neuroendocrine tumors","year":2013,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":373,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; University Health Network","funders":"National Cancer Institute; National Institute for Health and Care Research; Cancer Research UK","keywords":"Biology; Frameshift mutation; Somatic cell; Neuroendocrine tumors; Mutation; Germline mutation; Genetics; Exome; Cancer research; Gene; Cyclin-dependent kinase 6; Cell cycle; Exome sequencing; Cyclin; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.01501826094181791,"gpt":0.3044819130113842,"spread":0.2894636520695663,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004985729,0.0001641794,0.0003116041,0.0003002068,0.00001555445,0.00001233983,0.0001694968,0.00001559427,0.0001154869],"category_scores_gemma":[0.001153496,0.0001419387,0.00005448123,0.0004963239,0.00008492629,0.00005639773,0.00008903728,0.0007315861,0.00004359799],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000360056,"about_ca_system_score_gemma":0.00008250515,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003803212,"about_ca_topic_score_gemma":0.0000658024,"domain_scores_codex":[0.9985864,0.00005747525,0.0004083619,0.0002608177,0.0003183758,0.000368545],"domain_scores_gemma":[0.9989939,0.0001478296,0.0001120931,0.0003519965,0.0002473374,0.0001468799],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003323428,0.001224322,0.6187291,0.002346511,0.0000648598,0.01222156,0.0002318414,0.0008682147,0.3161448,0.0002285764,0.002060433,0.04554745],"study_design_scores_gemma":[0.003073947,0.001474041,0.5392609,0.0003647757,0.00004050614,0.004744589,0.0001726026,0.005406909,0.4408866,0.003389098,0.0009363581,0.0002496158],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956031,0.001036097,0.00002263163,0.001632866,0.0001056749,0.0008082119,0.000003375495,0.00004382368,0.0007442417],"genre_scores_gemma":[0.9911191,0.00009916345,0.007825898,0.0003398547,0.00007007641,0.00004444257,0.00001737587,0.00003514765,0.0004489368],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1247419,"threshold_uncertainty_score":0.5788093,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2625330427","doi":"10.1097/mpa.0000000000000850","title":"The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors","year":2017,"lang":"en","type":"review","venue":"Pancreas","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":366,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Hospital","funders":"National Cancer Institute","keywords":"Lanreotide; Medicine; Neuroendocrine tumors; Carcinoid syndrome; Everolimus; Gastrinoma; Guideline; Midgut; Internal medicine; Octreotide; Gastrointestinal tract; Clinical trial; Gastroenterology; Oncology; Pathology; Somatostatin; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.116049412098992,"gpt":0.4383574249562415,"spread":0.3223080128572495,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005320247,0.0008962363,0.003722536,0.000138401,0.0004824324,0.00009232041,0.001106362,0.000008220648,0.00001268818],"category_scores_gemma":[0.005342037,0.0005719286,0.001067521,0.0004258685,0.002001533,0.00004811682,0.0008211918,0.0008427138,0.00001050018],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007696126,"about_ca_system_score_gemma":0.000742253,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002468406,"about_ca_topic_score_gemma":0.000239167,"domain_scores_codex":[0.9939259,0.0003585011,0.001823053,0.00117031,0.001415613,0.001306664],"domain_scores_gemma":[0.9929731,0.002178468,0.001569507,0.001841593,0.000683305,0.00075398],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003244711,0.0001265181,0.001473543,0.03344417,0.0008540615,0.01387652,0.000001852775,4.083244e-7,3.115532e-7,0.00009441336,0.02613072,0.923673],"study_design_scores_gemma":[0.001423292,0.0005610157,0.001249196,0.004507828,0.0007303017,0.02058971,0.00003505129,0.0000941392,0.000003317631,0.00001278044,0.9704136,0.0003798112],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001956058,0.9879147,0.000005970074,0.004905495,0.0003225774,0.00402669,0.0004391006,0.0001222011,0.0003072105],"genre_scores_gemma":[0.0004714983,0.9943078,0.00108501,0.0004015808,0.000461447,0.0007468751,0.00013789,0.0001945015,0.002193367],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9442828,"threshold_uncertainty_score":0.9996732,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2010084014","doi":"10.1097/pas.0b013e3181ce1447","title":"Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the Development of a Minimum Pathology Data Set","year":2010,"lang":"en","type":"article","venue":"The American Journal of Surgical Pathology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":354,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network","funders":"","keywords":"Grading (engineering); Molecular pathology; Neuroendocrine tumors; Medicine; Anatomical pathology; Pathology; Multidisciplinary approach; MEDLINE; Consensus conference; Medical physics; Immunohistochemistry; Internal medicine; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.05201684456582726,"gpt":0.3850896943300885,"spread":0.3330728497642613,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002778946,0.0002183207,0.001256647,0.0002030611,0.0001028003,0.000004150923,0.001467429,0.00001574651,0.00001578742],"category_scores_gemma":[0.005425508,0.0001058121,0.0001656746,0.0008082089,0.002550495,0.00004224989,0.0007048608,0.001109331,0.000002527807],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001619719,"about_ca_system_score_gemma":0.0005759365,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000148641,"about_ca_topic_score_gemma":0.00004332774,"domain_scores_codex":[0.9947732,0.0008811083,0.002847304,0.0003797706,0.0006414146,0.0004772109],"domain_scores_gemma":[0.9901245,0.001247155,0.006197216,0.001462996,0.0008018312,0.0001662908],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","study_design_scores_codex":[0.006593959,0.001061608,0.1277308,0.000364475,0.0002025684,0.03078591,0.003146196,0.0002763365,0.7681593,0.0003845682,0.0003686399,0.06092557],"study_design_scores_gemma":[0.003467067,0.005417414,0.2267907,0.0002424257,0.0003460964,0.6201805,0.005835449,0.0003167348,0.1277902,0.0009758461,0.008289374,0.0003481786],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.984331,0.0001013562,0.0002303038,0.01448805,0.0001605177,0.000572901,0.00003542339,0.000008758281,0.00007166993],"genre_scores_gemma":[0.9969615,0.00003970978,0.002483084,0.0003211078,0.0001222565,0.00002265263,0.000006020044,0.00002730758,0.00001631382],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6403692,"threshold_uncertainty_score":0.9397405,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4399369977","doi":"10.1016/s0140-6736(24)00701-3","title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","year":2024,"lang":"en","type":"article","venue":"The Lancet","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":324,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Genentech; Astellas Pharma; Eisai; Servier; Moderna; Yuhan; LG Chem; Advanced Accelerator Applications; Sanofi; Halozyme; Exelixis; Ipsen; BeiGene; Mirati Therapeutics; Handok; Amgen; Pfizer; Recordati Rare Diseases; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Octreotide; Medicine; Neuroendocrine tumour; Neuroendocrine tumors; DOTA; Urology; Internal medicine; Nuclear medicine; Somatostatin; Chemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.08115582454593431,"gpt":0.3982719218759983,"spread":0.317116097330064,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005416048,0.0009295798,0.002130515,0.0002614154,0.000558585,0.0005205351,0.001509556,0.00001342399,0.000155457],"category_scores_gemma":[0.0009648257,0.0005554081,0.0002986601,0.0006384648,0.0003265517,0.0007138807,0.0003565909,0.0007427245,0.00003244907],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003983591,"about_ca_system_score_gemma":0.0001963181,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008919276,"about_ca_topic_score_gemma":0.001051929,"domain_scores_codex":[0.993979,0.0008227949,0.00119338,0.001285472,0.0009093452,0.001810037],"domain_scores_gemma":[0.9914322,0.005401323,0.0005334624,0.002007801,0.0001748748,0.0004503188],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6760316,0.03100978,0.02401781,0.00311987,0.008080703,0.0880162,0.003993939,0.007330264,0.0253161,0.0001677223,0.00690949,0.1260065],"study_design_scores_gemma":[0.8520564,0.06866155,0.007892733,0.001421601,0.005393874,0.002807353,0.006595785,0.01887307,0.03144097,0.0002255019,0.003432481,0.001198666],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9799625,0.001814518,0.0003861123,0.005156443,0.001284225,0.01070091,0.0002304368,0.0003604494,0.0001044485],"genre_scores_gemma":[0.9924788,0.002143769,0.0006345526,0.0003050563,0.00100469,0.002054372,0.0001790815,0.0002487859,0.000950861],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1760248,"threshold_uncertainty_score":0.9996898,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2017082986","doi":"10.1038/sj.bjc.6603419","title":"A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas","year":2006,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":317,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Temsirolimus; Medicine; Pharmacodynamics; Rash; Internal medicine; Sirolimus; Everolimus; Adverse effect; Oncology; Pharmacology; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors; Biology; Pharmacokinetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02542672549639566,"gpt":0.4100298367940532,"spread":0.3846031112976576,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002209364,0.0001412423,0.0007195438,0.0002534055,0.00004668181,0.00001546741,0.0001405678,0.000006174901,0.00005469594],"category_scores_gemma":[0.0002008323,0.0001461101,0.0001089716,0.0002975714,0.0001649056,0.0002254577,0.00008772993,0.0006752887,2.790644e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000049806,"about_ca_system_score_gemma":0.000178428,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001391107,"about_ca_topic_score_gemma":0.002726883,"domain_scores_codex":[0.997533,0.0001704838,0.001163791,0.0002450795,0.0005457942,0.0003418884],"domain_scores_gemma":[0.9988829,0.0001074121,0.0004080173,0.0001292362,0.0002684082,0.0002040237],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00478139,0.01220163,0.5985174,0.0001811056,0.0001088099,0.1072108,0.00004397093,0.0002594644,0.01529796,0.000005050479,0.0006610373,0.2607314],"study_design_scores_gemma":[0.1076803,0.01993638,0.8179324,0.0006809371,0.000227643,0.04192047,0.00031616,0.0003731495,0.002938264,0.00009863453,0.007672654,0.0002230837],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879664,0.01066317,0.000001776021,0.0003395648,0.0002356169,0.0005761837,0.00001616748,0.000009166039,0.0001919676],"genre_scores_gemma":[0.9944215,0.004653357,0.0001105269,0.00009505322,0.0002999403,0.00001813572,0.000001070492,0.00002979692,0.0003706284],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2605083,"threshold_uncertainty_score":0.5958198,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2027871096","doi":"10.1210/jc.2006-2843","title":"Germline CDKN1B/p27Kip1 Mutation in Multiple Endocrine Neoplasia","year":2007,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"MEN1; Multiple endocrine neoplasia; Pituitary adenoma; Germline mutation; Germline; Acromegaly; Pituitary tumors; Cancer research; Adenoma; Medicine; Mutation; Genetics; Internal medicine; Biology; Gene; Hormone","retraction":null,"screen_n_in":null,"score":{"opus":0.06919613952960105,"gpt":0.4319606911926545,"spread":0.3627645516630534,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003680496,0.000314144,0.001506804,0.0006602778,0.00009931223,0.0000145741,0.0006200688,0.0000473753,0.0001753124],"category_scores_gemma":[0.01106243,0.0001989895,0.0004795462,0.0006174563,0.0007113412,0.0002899068,0.0001482097,0.002744229,0.00008030261],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004994886,"about_ca_system_score_gemma":0.000307695,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007549328,"about_ca_topic_score_gemma":0.0002282945,"domain_scores_codex":[0.9938247,0.0009265171,0.002898905,0.0003205047,0.0008870623,0.001142297],"domain_scores_gemma":[0.9918116,0.005420045,0.001124995,0.0005874723,0.0005734928,0.0004823781],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03845895,0.004634502,0.4862852,0.0001914863,0.001148548,0.1229808,0.0006117357,0.0005761213,0.02664443,0.003826248,0.004900892,0.3097411],"study_design_scores_gemma":[0.01804981,0.001583328,0.8293839,0.00008716374,0.0003730995,0.05145275,0.0005709586,0.0001326106,0.01853934,0.001419771,0.07818075,0.0002265009],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816449,0.003916538,0.0005328805,0.01102533,0.001348387,0.0005032373,0.000003772855,0.00004046234,0.0009845441],"genre_scores_gemma":[0.9895145,0.003209876,0.002875679,0.001874308,0.001881611,0.000005353405,0.000003968333,0.0000462426,0.0005884277],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3430988,"threshold_uncertainty_score":0.9995565,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2080448046","doi":"10.1002/jso.20179","title":"Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract","year":2005,"lang":"en","type":"review","venue":"Journal of Surgical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":232,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"World Health Organization","keywords":"Chromogranin A; Medicine; Gastrointestinal tract; Carcinoid tumors; Carcinoid syndrome; Endocrine system; Neuroendocrine tumors; Disease; Urinary system; Multiple endocrine neoplasia; Pathology; Internal medicine; Oncology; Gastroenterology; Immunohistochemistry; Hormone","retraction":null,"screen_n_in":null,"score":{"opus":0.05850326143569263,"gpt":0.4082562820785296,"spread":0.349753020642837,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000524527,0.0004508359,0.003775719,0.000723227,0.00006366969,0.00001135348,0.0007368781,0.00003391624,0.000135414],"category_scores_gemma":[0.002052593,0.0002413673,0.002003535,0.0007042881,0.0005120779,0.00008858586,0.0001795763,0.002300712,0.000006459333],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003793785,"about_ca_system_score_gemma":0.003131129,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000001765611,"about_ca_topic_score_gemma":0.000002242041,"domain_scores_codex":[0.9951767,0.0006268522,0.002296631,0.0003270561,0.0008561396,0.0007166691],"domain_scores_gemma":[0.9922608,0.003502299,0.002952567,0.0003676299,0.000403681,0.0005130508],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0008262717,0.001641968,0.002615309,0.00999228,0.000119006,0.05218479,0.000006423606,0.000005414321,0.000005914388,0.00008318871,0.002403064,0.9301164],"study_design_scores_gemma":[0.001470459,0.005273562,0.0002854852,0.005210804,0.0009064635,0.3102081,0.000008167212,0.000001491917,0.000009495415,0.00001234714,0.6765203,0.00009332732],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002396499,0.9913362,0.000006570679,0.002617455,0.0004298,0.002265092,0.00005053565,0.00001498113,0.0008828506],"genre_scores_gemma":[0.002587349,0.9941894,0.001088646,0.00006755495,0.001440701,0.0000654256,0.00000757536,0.000084614,0.0004687077],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.930023,"threshold_uncertainty_score":0.9995578,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4381512857","doi":"10.1111/jne.13318","title":"European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes","year":2023,"lang":"en","type":"article","venue":"Journal of Neuroendocrinology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":228,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pancreas Centre (Canada)","funders":"Novo Nordisk; Ipsen; Pfizer","keywords":"Gastrinoma; Glucagonoma; Insulinoma; Carcinoid syndrome; Neuroendocrine tumors; Medicine; Pancreas; Internal medicine; Multiple endocrine neoplasia; Hormone; Carcinoid tumour; Pancreatic neuroendocrine tumor; Endocrinology; Pancreatic polypeptide; Gastroenterology; Gastrin; Glucagon; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.04111683806557333,"gpt":0.3247125420256947,"spread":0.2835957039601214,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002717376,0.00075906,0.00163045,0.001037125,0.0004275813,0.0001131257,0.0008811207,0.000008048483,0.0002786037],"category_scores_gemma":[0.003419338,0.0006693302,0.001285728,0.0016068,0.0004336682,0.0005440667,0.000522964,0.001604531,0.0004439545],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001434862,"about_ca_system_score_gemma":0.000375041,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000136011,"about_ca_topic_score_gemma":0.000005370907,"domain_scores_codex":[0.9929906,0.0006386771,0.002011374,0.0009926072,0.001106786,0.002260023],"domain_scores_gemma":[0.995074,0.001309306,0.001092237,0.0008923021,0.0008658528,0.0007662852],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"case_report","study_design_gemma":"case_report","study_design_scores_codex":[0.003716685,0.0008411023,0.01808035,0.001500019,0.0008904596,0.4304009,0.00005680229,0.0009995011,0.1764649,0.0004256683,0.3608881,0.005735491],"study_design_scores_gemma":[0.01053466,0.008730524,0.08262935,0.0003329777,0.0006270798,0.4769323,0.0003993438,0.0008265218,0.0137699,0.0005527023,0.403994,0.0006706558],"study_design_candidate":"case_report","study_design_consensus":"case_report","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9625862,0.00149355,0.0001603306,0.02838346,0.002951135,0.001511318,0.00006752965,0.0006183707,0.002228137],"genre_scores_gemma":[0.9704412,0.003745634,0.002123028,0.006171246,0.001814297,0.0001400277,0.00003879256,0.0004413014,0.01508443],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.162695,"threshold_uncertainty_score":0.9995758,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2808357284","doi":"10.1038/s41588-018-0138-4","title":"A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors","year":2018,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; University Health Network","funders":"National Center for Research Resources; National Institutes of Health; National Cancer Institute; Irving Medical Center, Columbia University; Swedish Cancer Foundation","keywords":"Regulator; Biology; Neuroendocrine tumors; Cancer research; Malignancy; Computational biology; Transcriptome; Precision oncology; Bioinformatics; Precision medicine; Genetics; Gene; Gene expression; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.0289040411998264,"gpt":0.3707038492971502,"spread":0.3417998080973238,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002904105,0.0001707873,0.0003489829,0.0001955112,0.00006924731,0.00001009606,0.0004107958,0.00002912416,0.0000595302],"category_scores_gemma":[0.001828045,0.0001082411,0.00006022674,0.00064875,0.0001695613,0.00002480848,0.0003488203,0.001043237,0.00002120006],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007881189,"about_ca_system_score_gemma":0.0001526452,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007031513,"about_ca_topic_score_gemma":0.00002952111,"domain_scores_codex":[0.9979011,0.0002083154,0.0003737707,0.0004067638,0.0006079765,0.0005021201],"domain_scores_gemma":[0.9989191,0.0002746522,0.00009238291,0.0002741743,0.0002646065,0.0001750299],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.005643068,0.003012999,0.01641871,0.000466947,0.0001284306,0.007283812,0.00101908,0.00153428,0.893773,0.001197444,0.02846724,0.04105499],"study_design_scores_gemma":[0.003466102,0.008991485,0.02031341,0.0001019235,0.0001299809,0.004240251,0.0007806638,0.007816971,0.8483505,0.001224271,0.1042266,0.0003579159],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908745,0.00117077,0.0003955837,0.002067412,0.000357062,0.001233684,0.000009560107,0.00003696911,0.003854434],"genre_scores_gemma":[0.9837422,0.0001741813,0.01422633,0.001209508,0.0003698071,0.00005518127,0.000005877491,0.00002391321,0.0001929828],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07575932,"threshold_uncertainty_score":0.4532403,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4387364431","doi":"10.1111/jne.13343","title":"European Neuroendocrine Tumour Society ( <scp>ENETS</scp> ) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours","year":2023,"lang":"en","type":"article","venue":"Journal of Neuroendocrinology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Neuroendocrine tumour; Internal medicine; Neuroendocrine tumors; Endocrinology; Medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.03225352257574834,"gpt":0.3138966615955156,"spread":0.2816431390197672,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003385853,0.0009180199,0.001772259,0.001181707,0.0005014593,0.0001462272,0.001096588,0.00001659794,0.00009533764],"category_scores_gemma":[0.006449416,0.0008320253,0.001430189,0.001851153,0.000501073,0.0005996837,0.0006208515,0.002053927,0.0003795173],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001705901,"about_ca_system_score_gemma":0.0003895779,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001708327,"about_ca_topic_score_gemma":0.00001055417,"domain_scores_codex":[0.9916057,0.0007810809,0.002230005,0.001183259,0.00136522,0.002834762],"domain_scores_gemma":[0.9931595,0.002437291,0.001308587,0.001016742,0.001085717,0.000992124],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001388743,0.000952304,0.03518706,0.001208359,0.000793761,0.2182493,0.0001177765,0.003649791,0.2425202,0.0005441651,0.4902305,0.005158085],"study_design_scores_gemma":[0.01301614,0.009714503,0.1844815,0.0003536376,0.0008213713,0.2447001,0.0007842881,0.001849613,0.02809088,0.0005990898,0.5151253,0.0004636473],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9705239,0.001641992,0.0003371766,0.0185448,0.003266704,0.001618774,0.00007787963,0.0006497714,0.00333901],"genre_scores_gemma":[0.9630187,0.006767521,0.002325453,0.006127812,0.0029029,0.0001570833,0.00006147257,0.0005596629,0.01807935],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2144293,"threshold_uncertainty_score":0.9994131,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1891914108","doi":"10.2147/dddt.s84177","title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","year":2015,"lang":"en","type":"article","venue":"Drug Design Development and Therapy","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":208,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Foothills Medical Centre","funders":"American Society of Clinical Oncology","keywords":"Pasireotide; Octreotide; Medicine; Gastroenterology; Internal medicine; Somatostatin; Adverse effect; Neuroendocrine tumors; Carcinoid syndrome; Refractory (planetary science); Acromegaly; Hormone","retraction":null,"screen_n_in":null,"score":{"opus":0.04525629135987289,"gpt":0.3048283482362036,"spread":0.2595720568763307,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002915725,0.0002759708,0.0005501148,0.0004126267,0.00007155183,0.00003037198,0.00009456565,0.000003126884,0.00001284863],"category_scores_gemma":[0.0001369135,0.0002071526,0.00001358376,0.0004129501,0.00006609423,0.0002242323,0.00006346576,0.0001830255,0.000004127448],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005761496,"about_ca_system_score_gemma":0.0002426429,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001505529,"about_ca_topic_score_gemma":0.00006789016,"domain_scores_codex":[0.9977878,0.0002526574,0.0004936168,0.0004555457,0.0005889701,0.0004213784],"domain_scores_gemma":[0.9988588,0.0001776733,0.0001595853,0.0002264936,0.0001760113,0.0004014263],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01546522,0.00541127,0.9282393,0.0001332527,0.0001966031,0.004000307,0.007592705,0.00003227893,0.000689056,0.000002185745,0.0002887951,0.03794898],"study_design_scores_gemma":[0.2588125,0.04743521,0.5567341,0.0009147707,0.0001575626,0.000467135,0.01416606,0.0002800501,0.1164324,0.00007036859,0.0029399,0.001590035],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972265,0.0004265823,0.00007526609,0.00006944102,0.00002246271,0.002108704,0.000002829362,0.00003576893,0.00003245862],"genre_scores_gemma":[0.9969729,0.00008248774,0.002361478,0.0001188509,0.000007875717,0.0001160122,0.00001978052,0.00004241232,0.0002782394],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3715053,"threshold_uncertainty_score":0.8447438,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1997380178","doi":"10.1159/000461583","title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors","year":2017,"lang":"en","type":"article","venue":"Neuroendocrinology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":201,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pancreas Centre (Canada)","funders":"Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; National Institutes of Health; Peking Union Medical College; Fakultet Medicinskih Nauka, Univerziteta U Kragujevcu; Haukeland Universitetssjukehus; Peking Union Medical College Hospital; Institut Gustave-Roussy; Hospices Civils de Lyon; Università Cattolica del Sacro Cuore; Peter MacCallum Cancer Centre; National and Kapodistrian University of Athens; Medizinische Universität Wien; Uppsala Universitet; Akademiska Sjukhuset; University of Bern; Universität Wien; Gentofte Hospital; Chinese Academy of Medical Sciences","keywords":"Carcinoid syndrome; Gastrinoma; Medicine; Glucagonoma; Insulinoma; Neuroendocrine tumors; Somatostatin; Lanreotide; Octreotide; Carcinoid Heart Disease; Internal medicine; Carcinoid tumors; Perioperative; Endocrinology; Hormone; Gastroenterology; Surgery; Insulin; Gastrin","retraction":null,"screen_n_in":null,"score":{"opus":0.03445480310458621,"gpt":0.3687721676926212,"spread":0.334317364588035,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00005356974,0.0006174085,0.001250732,0.0005033722,0.0003594898,0.00008698284,0.0007085394,0.00001026078,0.00002482057],"category_scores_gemma":[0.00385234,0.0004172274,0.0001343217,0.0002565313,0.001372488,0.0002233226,0.0004412422,0.0007934544,0.00000110542],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001028402,"about_ca_system_score_gemma":0.0004428779,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005487821,"about_ca_topic_score_gemma":0.001468193,"domain_scores_codex":[0.9954712,0.0002905244,0.001060011,0.00109207,0.0007977347,0.001288404],"domain_scores_gemma":[0.9956142,0.0006863579,0.0004841032,0.00147712,0.001518188,0.0002200298],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02114883,0.0004832598,0.9441178,0.0004166284,0.00007548766,0.01038605,0.0002158628,0.0003643776,0.001231032,0.0003509686,0.0003581732,0.02085148],"study_design_scores_gemma":[0.02403738,0.01322319,0.9331958,0.0002576266,0.00004331066,0.002918494,0.0003930118,0.0002359451,0.01173492,0.00003857131,0.01358657,0.0003351475],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9818246,0.001928634,0.000003020192,0.01131195,0.0002199594,0.004173925,0.0002400318,0.0000573103,0.0002405578],"genre_scores_gemma":[0.9948228,0.003016451,0.0002812619,0.0009448689,0.00008904211,0.0004655269,0.00002244094,0.0001182276,0.0002393776],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02051633,"threshold_uncertainty_score":0.999828,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1772419959","doi":"10.1158/1078-0432.ccr-15-0373","title":"Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cancer Research UK","keywords":"Biology; Exome; Copy number analysis; Exome sequencing; Epigenomics; Gene expression profiling; Transcriptome; Carcinogenesis; Cancer research; Genetics; Gene; Genome; Copy-number variation; DNA methylation; Gene expression; Phenotype","retraction":null,"screen_n_in":null,"score":{"opus":0.3227779994311764,"gpt":0.5517655373498642,"spread":0.2289875379186878,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001625994,0.0002140195,0.0008294565,0.0004005382,0.0000322983,0.00001647706,0.0005478857,0.000011526,0.0001609506],"category_scores_gemma":[0.02841181,0.0001619726,0.0003617259,0.001142989,0.001349146,0.00008374936,0.0005045192,0.001400875,0.00002375723],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000159834,"about_ca_system_score_gemma":0.002892039,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001309645,"about_ca_topic_score_gemma":0.00007579685,"domain_scores_codex":[0.9953912,0.0005198195,0.001028088,0.0005870445,0.001567465,0.0009064222],"domain_scores_gemma":[0.9934331,0.001971981,0.0002212805,0.0007568228,0.002621378,0.0009954139],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007739788,0.002956655,0.9336494,0.0007034038,0.0001896741,0.00743736,0.00002240688,0.0002693821,0.04039689,0.0002587727,0.002446504,0.003929807],"study_design_scores_gemma":[0.02553437,0.06473021,0.7313905,0.002182728,0.0002816397,0.005854447,0.000307093,0.004869206,0.1587983,0.001764145,0.003588601,0.0006987097],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995222,0.001051034,0.0000625244,0.001170355,0.0001189523,0.001088636,0.00004124289,0.00003794994,0.001207343],"genre_scores_gemma":[0.9975082,0.0001587887,0.001536097,0.00007095732,0.0001821755,0.0001075035,0.000008603984,0.00005802362,0.0003696074],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2022588,"threshold_uncertainty_score":0.9797723,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2029658908","doi":"10.1097/mpa.0b013e3181ec1380","title":"NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors","year":2010,"lang":"en","type":"article","venue":"Pancreas","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":199,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Neuroendocrine tumors; Guideline; Foregut; Disease; Thorax (insect anatomy); Epidemiology; Internal medicine; Incidence (geometry); Pathology; Intensive care medicine; Oncology","retraction":null,"screen_n_in":null,"score":{"opus":0.03142724757510493,"gpt":0.3461938224640186,"spread":0.3147665748889137,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001522796,0.0001334581,0.0002568503,0.00006152454,0.00007342116,0.00001123456,0.0001299116,0.000003294032,0.00008288056],"category_scores_gemma":[0.0005646127,0.00008718159,0.00006602097,0.0001241865,0.0002273323,0.00002240641,0.0001106225,0.0001811243,0.000005352138],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000005889946,"about_ca_system_score_gemma":0.00002610769,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001331567,"about_ca_topic_score_gemma":0.00005181789,"domain_scores_codex":[0.9988174,0.00002461682,0.0003250498,0.0002494848,0.000262143,0.0003213456],"domain_scores_gemma":[0.9986201,0.0005879591,0.00008886366,0.0004187715,0.0001339416,0.0001503885],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.006721737,0.001809839,0.2657657,0.006430284,0.001462744,0.02275336,0.0001094327,0.00004733949,0.09458068,0.03363809,0.2897815,0.2768993],"study_design_scores_gemma":[0.004914554,0.0008932221,0.07478194,0.0001694201,0.000396093,0.005815621,0.0001941927,0.0008299391,0.06116521,0.0008591783,0.8497608,0.0002197756],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9785091,0.001111392,0.00003196833,0.01690746,0.0001958601,0.00180094,0.00005120142,0.00005238086,0.001339726],"genre_scores_gemma":[0.9897271,0.001642999,0.006759284,0.0005635319,0.0001169656,0.0003562898,0.00001091985,0.00003071877,0.0007921651],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5599793,"threshold_uncertainty_score":0.3555162,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4210985377","doi":"10.1097/mpa.0000000000001597","title":"The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors","year":2020,"lang":"en","type":"article","venue":"Pancreas","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Neuroendocrine tumors; Medicine; Panel discussion; Consensus conference; Pancreatic neuroendocrine tumor; Internal medicine; MEDLINE; Oncology; General surgery; Family medicine; Political science","retraction":null,"screen_n_in":null,"score":{"opus":0.0424856462181673,"gpt":0.3439728744761427,"spread":0.3014872282579754,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002062248,0.0003543266,0.0008609918,0.00004059664,0.0002031052,0.00003270799,0.0003637709,0.000002299844,0.0000171392],"category_scores_gemma":[0.003702473,0.0002466229,0.0002421706,0.0005985511,0.0009300655,0.00004039309,0.0003275425,0.0003315572,0.000006401881],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002540399,"about_ca_system_score_gemma":0.0001731183,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001684929,"about_ca_topic_score_gemma":0.00009198603,"domain_scores_codex":[0.9965265,0.0001563706,0.0008506266,0.0006582557,0.0009865279,0.0008216536],"domain_scores_gemma":[0.9968247,0.001140188,0.0003152622,0.0005124634,0.0004510008,0.0007564101],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009336534,0.0005512674,0.7342803,0.006806518,0.001693564,0.0369561,0.00008908998,0.00008372873,0.001256903,0.001290265,0.1292879,0.07836787],"study_design_scores_gemma":[0.01710743,0.007053118,0.5337073,0.0005987619,0.0007775781,0.02544328,0.002184087,0.03151967,0.004377973,0.0001827893,0.3758232,0.001224873],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.92461,0.00170865,0.00006794443,0.07154696,0.00008007824,0.001523077,0.0000970457,0.0001469053,0.0002193726],"genre_scores_gemma":[0.98484,0.005504687,0.003200648,0.005526076,0.0002707608,0.0002097136,0.00002962152,0.00008287794,0.00033559],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2465353,"threshold_uncertainty_score":0.9999986,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2549249508","doi":"10.1093/annonc/mdw561","title":"Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Laurentian University; McGill University Health Centre","funders":"","keywords":"Medicine; Sunitinib; Placebo; Internal medicine; Clinical endpoint; Neuroendocrine tumors; Progression-free survival; Confidence interval; Oncology; Randomized controlled trial; Surgery; Overall survival; Cancer; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.09109473406666649,"gpt":0.4336538198558955,"spread":0.342559085789229,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009949211,0.0003325947,0.002208543,0.0003861397,0.00005068541,0.00001460823,0.0003372115,0.00001919914,0.0005095697],"category_scores_gemma":[0.004804675,0.0002130494,0.0001457565,0.000287968,0.0006238063,0.0002143116,0.0004032362,0.0003635097,0.00001024539],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003446767,"about_ca_system_score_gemma":0.0003086986,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008814748,"about_ca_topic_score_gemma":0.0005649696,"domain_scores_codex":[0.9949804,0.001898279,0.001078031,0.0006217701,0.0006739607,0.0007475569],"domain_scores_gemma":[0.9947891,0.003520856,0.0003837777,0.0006540152,0.0003074834,0.0003448246],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7585875,0.0146314,0.104333,0.0001381313,0.0006761047,0.0549912,0.0003389027,0.000001319397,0.02222584,0.000685822,0.003627466,0.03976334],"study_design_scores_gemma":[0.9275699,0.01937227,0.03503959,0.0004031217,0.0001900833,0.0006258741,0.0006010396,0.00005923335,0.008018802,0.003071477,0.004711499,0.0003370781],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9839203,0.0003204603,0.000008270458,0.01154799,0.0001624906,0.002457184,0.0001068374,0.00006320415,0.001413235],"genre_scores_gemma":[0.9978288,0.0007199778,0.0002021535,0.0002892778,0.000154452,0.0002352051,0.00004706151,0.00004207041,0.0004809705],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1689824,"threshold_uncertainty_score":0.8687903,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2102617530","doi":"10.2967/jnumed.113.125336","title":"Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-Octreotate","year":2014,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"Erasmus Medisch Centrum","keywords":"Neuroendocrine tumors; Radionuclide therapy; Medicine; Progressive disease; Internal medicine; Confidence interval; Gastroenterology; Cohort; Oncology; Nuclear medicine; Disease","retraction":null,"screen_n_in":null,"score":{"opus":0.009342735578978306,"gpt":0.2542127342842936,"spread":0.2448699987053153,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002987863,0.0004976876,0.001558112,0.0008509535,0.00004643597,0.00001903414,0.0003727425,0.00001483436,0.0006481427],"category_scores_gemma":[0.0004036967,0.0002857402,0.0001607537,0.0004937712,0.0005124295,0.0003444684,0.000067521,0.0009472629,0.00001445119],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001426533,"about_ca_system_score_gemma":0.00006384961,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002843023,"about_ca_topic_score_gemma":0.000009622316,"domain_scores_codex":[0.9953421,0.0003418987,0.001516008,0.0004072674,0.001650902,0.0007417989],"domain_scores_gemma":[0.9971411,0.0001811974,0.0009792078,0.0005494677,0.0005203679,0.0006287209],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02124434,0.0009144572,0.9713568,0.0002729035,0.0002768943,0.003393725,0.0002556343,0.0001153567,0.0009384691,0.0000015088,0.0006622309,0.0005676914],"study_design_scores_gemma":[0.02699581,0.02597225,0.9405611,0.002564332,0.0002083815,0.00214747,0.0002024268,0.0001059633,0.0003395981,0.000002661077,0.0007176728,0.0001822941],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996705,0.0001180676,0.00001500247,0.002131997,0.0001201855,0.0007257685,0.00000756256,0.00003237891,0.0001440518],"genre_scores_gemma":[0.9979201,0.0003130542,0.0003361259,0.0008018856,0.0002622791,0.000006321258,0.00001905438,0.0001489388,0.0001922519],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03079566,"threshold_uncertainty_score":0.9999595,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2902656640","doi":"10.1007/s00259-018-4209-7","title":"Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial","year":2018,"lang":"en","type":"article","venue":"European Journal of Nuclear Medicine and Molecular Imaging","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":184,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôtel-Dieu de Québec; Université Laval","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Centre Hospitalier Universitaire de Québec","keywords":"Radionuclide therapy; Medicine; Neuroendocrine tumors; Nuclear medicine; Renal function; Peptide receptor; Internal medicine; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.03616051517727272,"gpt":0.3281846418662204,"spread":0.2920241266889477,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001061289,0.0002716272,0.0006245216,0.0002236804,0.0001517984,0.00004049559,0.0003913454,0.000003355113,0.0002139886],"category_scores_gemma":[0.002665807,0.0001679905,0.0002107152,0.0002561829,0.001179034,0.0001799241,0.0001326472,0.0006601784,0.0000201758],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002403583,"about_ca_system_score_gemma":0.00007829472,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000492792,"about_ca_topic_score_gemma":6.477745e-7,"domain_scores_codex":[0.9963248,0.001049921,0.001030228,0.0003327177,0.0008684914,0.0003938426],"domain_scores_gemma":[0.9977062,0.0003670811,0.0006951849,0.0004246514,0.0004630366,0.0003438876],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1910281,0.0003732473,0.0004106286,0.00004117322,0.00046745,0.05681379,0.004436845,0.000001516587,0.5251698,0.0001035908,0.188894,0.03225979],"study_design_scores_gemma":[0.1621153,0.01172114,0.002256704,0.001272069,0.0002782112,0.01263435,0.003655268,0.0001016635,0.01729579,0.00006932727,0.7882988,0.0003014079],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9353426,0.002210303,0.00005081881,0.05699562,0.0005552011,0.0004120312,0.00001841061,0.00003073775,0.00438431],"genre_scores_gemma":[0.9832247,0.002686967,0.001265984,0.01021664,0.002410806,7.156812e-7,0.00001120824,0.0001100094,0.00007291674],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5994048,"threshold_uncertainty_score":0.6850452,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2148881212","doi":"10.1200/jco.2011.37.2151","title":"Cohort Study of Somatostatin-Based Radiopeptide Therapy With [<sup>90</sup>Y-DOTA]-TOC Versus [<sup>90</sup>Y-DOTA]-TOC Plus [<sup>177</sup>Lu-DOTA]-TOC in Neuroendocrine Cancers","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":184,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"DOTA; Medicine; Nuclear medicine; Toxicity; Radionuclide therapy; Internal medicine; Chelation; Chemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.1020687681331224,"gpt":0.4514493292812904,"spread":0.349380561148168,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.005078877,0.001546272,0.007297655,0.001503453,0.000303449,0.0000980539,0.001939022,0.0002326326,0.0009109227],"category_scores_gemma":[0.008809499,0.001179045,0.001337425,0.001917611,0.001802702,0.001204347,0.0004659872,0.006544166,0.0001026967],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00191634,"about_ca_system_score_gemma":0.007683575,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001199749,"about_ca_topic_score_gemma":0.00102017,"domain_scores_codex":[0.97845,0.004434632,0.008111032,0.001683383,0.004063684,0.003257287],"domain_scores_gemma":[0.9774672,0.01146228,0.004524863,0.002041974,0.001659241,0.002844376],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1093278,0.01521421,0.7483701,0.0003529033,0.002851752,0.03975453,0.001184834,0.06076151,0.0002740753,0.00006847556,0.009195401,0.01264436],"study_design_scores_gemma":[0.304484,0.2151193,0.2936257,0.001514658,0.003201677,0.01534829,0.01761791,0.02428376,0.001872928,0.000159849,0.1199189,0.002852944],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9836044,0.001555304,0.00004860675,0.005994007,0.001051861,0.005498362,0.00007617979,0.0001303738,0.002040868],"genre_scores_gemma":[0.9871983,0.001964668,0.003211553,0.003331893,0.002821986,0.0004063677,0.00003624571,0.0003651005,0.0006638744],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4547444,"threshold_uncertainty_score":0.9997286,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2002682545","doi":"10.1200/jco.2003.01.501","title":"Small-Cell Carcinoma of the Cervix: Fourteen Years of Experience at a Single Institution Using a Combined-Modality Regimen of Involved-Field Irradiation and Platinum-Based Combination Chemotherapy","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Carboplatin; Etoposide; Regimen; Chemotherapy; Radiation therapy; Cervix; Cisplatin; Surgery; Internal medicine; Oncology; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1457367224923363,"gpt":0.4208430608762069,"spread":0.2751063383838706,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001039519,0.00007871144,0.0006801863,0.0001005856,0.00002755164,0.0000023906,0.0001240398,0.00005813875,0.00001718296],"category_scores_gemma":[0.003552069,0.00005993817,0.0001683515,0.0001901565,0.0003598145,0.00008867685,0.00003674536,0.0003158576,1.159582e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001277947,"about_ca_system_score_gemma":0.0007993809,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007837317,"about_ca_topic_score_gemma":0.00004924911,"domain_scores_codex":[0.9975914,0.0004987985,0.001291638,0.0001223687,0.0003685489,0.0001271933],"domain_scores_gemma":[0.9959534,0.001366898,0.001985389,0.0001933104,0.0003938013,0.000107172],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004489709,0.002826177,0.9010947,0.0002437409,0.00005451099,0.00009468207,0.0004087153,0.0001677174,0.08391251,0.0004878284,0.00005108381,0.006168643],"study_design_scores_gemma":[0.01859134,0.01753189,0.6731267,0.0001936809,0.0001232628,0.0001473857,0.0003806324,0.001404674,0.2868327,0.001101171,0.0004774683,0.00008906458],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9976053,0.000116728,0.0001576755,0.001291945,0.0001950547,0.000287075,0.000001486494,0.000001954339,0.0003428055],"genre_scores_gemma":[0.9969223,0.00004675313,0.002677984,0.0002895858,0.00003620141,0.000001597244,5.172173e-7,0.000007478348,0.00001756616],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.227968,"threshold_uncertainty_score":0.4252415,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2133606607","doi":"10.2967/jnumed.107.045708","title":"6-l-<sup>18</sup>F-Fluorodihydroxyphenylalanine PET in Neuroendocrine Tumors: Basic Aspects and Emerging Clinical Applications","year":2008,"lang":"en","type":"review","venue":"Journal of Nuclear Medicine","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"","keywords":"Neuroendocrine tumors; Medicine; Nuclear medicine; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.07041180289222383,"gpt":0.414401556093235,"spread":0.3439897532010112,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007487804,0.0007663621,0.005128331,0.001662841,0.0001247559,0.00002599146,0.0006336806,0.0000416021,0.0006703417],"category_scores_gemma":[0.002628472,0.0005428267,0.0006790958,0.001225025,0.0007628807,0.0002594065,0.0002933512,0.003823115,0.00007578193],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002223378,"about_ca_system_score_gemma":0.0005981135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002120374,"about_ca_topic_score_gemma":0.000003248088,"domain_scores_codex":[0.9927374,0.0006139255,0.003647543,0.0007711467,0.001398033,0.0008319892],"domain_scores_gemma":[0.9949632,0.001093216,0.001701194,0.0008192784,0.0003393024,0.001083777],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004792262,0.00117866,0.0005387272,0.01474974,0.0005386082,0.1914583,0.000130964,0.00001312346,0.00001488023,0.0002100525,0.05069524,0.7399924],"study_design_scores_gemma":[0.003031056,0.002280319,0.0001710256,0.01485051,0.000563078,0.1988019,0.0001197808,0.00007431029,3.268523e-7,0.00006238918,0.7797938,0.000251499],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001808575,0.9896688,0.000004438819,0.004372438,0.0002063072,0.001662191,0.00001208139,0.00006249503,0.002202635],"genre_scores_gemma":[0.001116016,0.9939906,0.0005252627,0.0007186307,0.003035301,0.00002183376,0.00002360146,0.0002336211,0.0003351595],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7397409,"threshold_uncertainty_score":0.9997023,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2528882268","doi":"10.1002/bjs.10312","title":"Systematic review of active surveillance <i>versus</i> surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms","year":2016,"lang":"en","type":"review","venue":"British journal of surgery","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":175,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Medicine; Asymptomatic; Incidence (geometry); Conservative management; Surgery; Retrospective cohort study; Watchful waiting; Cochrane Library; Internal medicine; General surgery; Meta-analysis; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.03889656474981849,"gpt":0.3258654374501556,"spread":0.2869688727003371,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001691549,0.0005782261,0.009644892,0.0006409697,0.0000574457,0.00003393372,0.000471707,0.00003084834,0.0001633198],"category_scores_gemma":[0.003009479,0.0004514136,0.002523683,0.000912895,0.0002105229,0.0002347298,0.0001928328,0.0007959251,0.00002026879],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000220272,"about_ca_system_score_gemma":0.0006282719,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001566741,"about_ca_topic_score_gemma":0.000002402721,"domain_scores_codex":[0.9912134,0.00120519,0.004889391,0.0004406458,0.001591908,0.0006594718],"domain_scores_gemma":[0.9861274,0.006159044,0.00577373,0.0006534076,0.0009001921,0.0003861607],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0001958611,0.000179772,0.00003320117,0.8235019,0.001945355,0.04628946,0.000001119995,1.901124e-7,4.938782e-7,0.000003156421,0.0006866605,0.1271628],"study_design_scores_gemma":[0.001160375,0.000271635,0.00005954728,0.8548111,0.003449222,0.125104,0.0000197949,4.912346e-7,0.00001293874,0.000003463472,0.01486213,0.0002452692],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0007107313,0.9956495,0.00002029928,0.00005882193,0.0007722538,0.002116141,0.00009760656,0.00002120063,0.0005534769],"genre_scores_gemma":[0.0002234907,0.9985198,0.0001679589,0.00002718326,0.0001820674,0.0001084485,0.00002954449,0.0001171532,0.000624383],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.1269175,"threshold_uncertainty_score":0.9997938,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3035208766","doi":"10.1158/1078-0432.ccr-20-0621","title":"Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Sierra Oncology; Australian Government; Eisai; BeiGene; Sanofi; Clovis Oncology; AstraZeneca; Bristol-Myers Squibb; Amgen","keywords":"Nivolumab; Ipilimumab; Medicine; Clinical endpoint; Internal medicine; Clinical trial; Response Evaluation Criteria in Solid Tumors; Progressive disease; Neuroendocrine tumors; Immunotherapy; Gastroenterology; Oncology; Phases of clinical research; Surgery; Cancer; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.1458014106400074,"gpt":0.4961921606803399,"spread":0.3503907500403325,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001470422,0.0002441928,0.001704492,0.0003599932,0.00009303367,0.0000185419,0.0006137465,0.00003114099,0.0001105953],"category_scores_gemma":[0.006608485,0.0001614958,0.0005345456,0.002909325,0.001596703,0.0001366916,0.0003280425,0.001402714,7.528396e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001749352,"about_ca_system_score_gemma":0.001408621,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007027938,"about_ca_topic_score_gemma":0.00122785,"domain_scores_codex":[0.9937112,0.001153005,0.001866436,0.0009472796,0.001491744,0.000830356],"domain_scores_gemma":[0.9940512,0.003204938,0.0004603309,0.0008381965,0.0009859144,0.000459474],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2936655,0.0007833738,0.6875437,0.0002876415,0.0005891466,0.00006400538,0.00006950834,0.0001108508,0.000108332,0.00001699664,0.000290285,0.01647068],"study_design_scores_gemma":[0.183851,0.02587579,0.7853873,0.0002820395,0.0003110554,0.000002682378,0.0001958816,0.0008119371,0.0006916141,0.00003996356,0.002360493,0.0001901549],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909365,0.0007371737,0.000007564159,0.00373121,0.0001459086,0.004184535,0.0001975754,0.0000170141,0.00004257075],"genre_scores_gemma":[0.9970787,0.001534423,0.0001724321,0.0004583442,0.0001833995,0.0004029752,0.00002134764,0.00005643931,0.000091898],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1098145,"threshold_uncertainty_score":0.7911451,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2021926444","doi":"10.1038/sj.bjc.6601104","title":"A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma","year":2003,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Hypercalcaemia; Chemotherapy; Internal medicine; Progressive disease; Gastroenterology; Toxicity; Cancer; Oncology; Vitamin D and neurology; Surgery; Calcium","retraction":null,"screen_n_in":null,"score":{"opus":0.0134465700079132,"gpt":0.2953229735743543,"spread":0.2818764035664411,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001779763,0.0001036529,0.0003846743,0.0001245158,0.0000709126,0.00001542344,0.000160963,0.00000785782,0.00008251214],"category_scores_gemma":[0.0001991111,0.00007527321,0.00006291558,0.0004478234,0.00007908295,0.0001599094,0.00003682465,0.000438668,2.850673e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001109438,"about_ca_system_score_gemma":0.000319137,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008452375,"about_ca_topic_score_gemma":0.001366123,"domain_scores_codex":[0.9982221,0.0001874188,0.0004412861,0.0001413424,0.0007476247,0.0002602765],"domain_scores_gemma":[0.9990103,0.00002645681,0.0002397909,0.00016977,0.0004277814,0.0001258802],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006790707,0.004700365,0.9844826,0.00004380668,0.00005928267,0.004346225,0.0001317908,0.00006040664,0.0004349953,0.000002093259,0.0002076495,0.004851732],"study_design_scores_gemma":[0.0510089,0.01698727,0.914723,0.0009231806,0.0001238612,0.002349224,0.0007234539,0.00003564279,0.01063007,0.00001750645,0.002324859,0.0001530656],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9976073,0.001434837,0.000003431472,0.00006864857,0.00009549592,0.0006550659,0.00001305682,0.000002392807,0.000119795],"genre_scores_gemma":[0.9995396,0.00009215336,0.00004897139,0.00007784736,0.00003386183,0.0000179803,6.896764e-7,0.00001897441,0.0001699132],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06975961,"threshold_uncertainty_score":0.3069552,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4377137097","doi":"10.1111/jne.13306","title":"European Neuroendocrine Tumor Society ( <scp>ENETS</scp> ) 2023 guidance paper for gastroduodenal neuroendocrine tumours ( <scp>NETs) G1–G3</scp>","year":2023,"lang":"en","type":"article","venue":"Journal of Neuroendocrinology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pancreas Centre (Canada)","funders":"Universidad de Córdoba; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; University College London; Philipps-Universität Marburg","keywords":"Neuroendocrine tumors; Neuroendocrine tumour; Internal medicine; Medicine; Endocrinology; Gastroenterology; Cancer research","retraction":null,"screen_n_in":null,"score":{"opus":0.02839168042675754,"gpt":0.3101567929401639,"spread":0.2817651125134064,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005061189,0.001543297,0.002638052,0.001670199,0.0006257861,0.000245658,0.002231745,0.00002316699,0.00008290322],"category_scores_gemma":[0.01115704,0.001421585,0.002118708,0.002405122,0.0009733498,0.0008626402,0.001303422,0.00350049,0.0006562212],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002470314,"about_ca_system_score_gemma":0.000749791,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002224141,"about_ca_topic_score_gemma":0.00001562665,"domain_scores_codex":[0.9862747,0.001274521,0.003232989,0.002005369,0.002237961,0.004974439],"domain_scores_gemma":[0.9889752,0.003747758,0.002085794,0.001797331,0.001536593,0.001857302],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004575999,0.0008751988,0.0177323,0.0006553375,0.0004967956,0.2221166,0.00008201708,0.001961507,0.08694673,0.0002613145,0.6662123,0.00220234],"study_design_scores_gemma":[0.009616208,0.007488462,0.06647407,0.0002111954,0.0004403853,0.2293338,0.0005680534,0.000841105,0.02483239,0.000363791,0.6595882,0.0002423884],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9668339,0.002623238,0.0001973881,0.01944423,0.004096974,0.002287419,0.0002602472,0.0008734288,0.003383184],"genre_scores_gemma":[0.9070539,0.01414678,0.005021805,0.02055365,0.007164907,0.0003656051,0.0001849876,0.001543049,0.04396535],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06211435,"threshold_uncertainty_score":0.9997315,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2090438424","doi":"10.1245/s10434-010-0949-8","title":"Parenchyma-Preserving Resections for Small Nonfunctioning Pancreatic Endocrine Tumors","year":2010,"lang":"en","type":"article","venue":"Annals of Surgical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Medicine; Enucleation; Endocrine system; Pancreatic fistula; Malignancy; Lymph node; Neuroendocrine tumors; Surgery; Pancreatectomy; Perioperative; Internal medicine; Gastroenterology; Pancreas","retraction":null,"screen_n_in":null,"score":{"opus":0.1082438723033879,"gpt":0.4198643202523934,"spread":0.3116204479490056,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004195063,0.0001692011,0.0006374024,0.0002536708,0.0001432134,0.00001270521,0.0002014558,0.00003391937,0.0007376641],"category_scores_gemma":[0.001216809,0.0001427865,0.0002369477,0.0003329045,0.0002842245,0.0001117175,0.0001439445,0.000631007,0.00002243884],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002093499,"about_ca_system_score_gemma":0.000267168,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001973485,"about_ca_topic_score_gemma":0.0003484456,"domain_scores_codex":[0.9980721,0.0001068813,0.0005250557,0.0003713897,0.0002669556,0.0006575771],"domain_scores_gemma":[0.996695,0.001772625,0.000171202,0.0004063061,0.0005977377,0.0003571317],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.02710925,0.01009168,0.1523839,0.003868858,0.001681749,0.04706552,0.0004729122,0.0004584539,0.3694801,0.04781715,0.1405321,0.1990383],"study_design_scores_gemma":[0.002732705,0.004085453,0.00369489,0.00008184971,0.00005630737,0.004622026,0.0001276333,0.0002951277,0.03748838,0.002105073,0.9445509,0.0001596883],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9316524,0.000219746,0.00009294267,0.02581621,0.0004456727,0.0008503448,0.00002343363,0.00009955937,0.04079971],"genre_scores_gemma":[0.9901595,0.0007876899,0.003463275,0.0003618688,0.0006599997,0.0002948273,0.00003503458,0.00003625953,0.004201616],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8040187,"threshold_uncertainty_score":0.8076905,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2418960531","doi":"10.1200/jgo.2015.002980","title":"Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs","year":2016,"lang":"en","type":"article","venue":"Journal of Global Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Mount Sinai Hospital","funders":"Akademiska Sjukhuset; Uppsala Universitet; University of Toronto; Carcinoid Cancer Foundation","keywords":"Medicine; Family medicine; Neuroendocrine tumors; Disease; Health care; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.02169943297907707,"gpt":0.3187933873515484,"spread":0.2970939543724713,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003131476,0.0002480526,0.0009957291,0.00005627392,0.00004562466,0.000008423943,0.0004316201,0.00001501713,0.00005934385],"category_scores_gemma":[0.006621213,0.000120486,0.0001694089,0.0005721978,0.0004492886,0.0001794086,0.0002064321,0.0002581805,0.000005184985],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004616787,"about_ca_system_score_gemma":0.0008547481,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003299804,"about_ca_topic_score_gemma":0.002551954,"domain_scores_codex":[0.995945,0.0004767597,0.001653124,0.000307001,0.001133054,0.0004850911],"domain_scores_gemma":[0.993321,0.001542828,0.002480879,0.0005085868,0.001836428,0.0003103011],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02280475,0.001011324,0.9404003,0.00001856388,0.0003309179,0.007514431,0.00002082667,0.0000315668,0.00006049253,0.000008828286,0.02108142,0.006716579],"study_design_scores_gemma":[0.01388963,0.01422644,0.9444583,0.0003520403,0.0001814673,0.002202036,0.00004894888,0.000003221098,0.0004582072,0.00008720053,0.02399369,0.00009882549],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9881438,0.0003560823,0.000006674125,0.008967091,0.0003829548,0.000534768,0.001154929,0.0000105442,0.0004431768],"genre_scores_gemma":[0.9989543,0.0001664087,0.0002486378,0.0004500622,0.0001296727,0.000009217611,0.00001550156,0.00001599382,0.00001022739],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01321512,"threshold_uncertainty_score":0.7926689,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2064587699","doi":"10.1359/jbmr.090304","title":"Sporadic and MEN1-Related Primary Hyperparathyroidism: Differences in Clinical Expression and Severity","year":2009,"lang":"en","type":"article","venue":"Journal of Bone and Mineral Research","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"","keywords":"MEN1; Primary hyperparathyroidism; Medicine; Multiple endocrine neoplasia; Parathyroid hormone; Internal medicine; Hyperparathyroidism; Gastroenterology; Endocrine disease; Urinary system; Endocrinology; Urology; Endocrine system; Hormone; Calcium","retraction":null,"screen_n_in":null,"score":{"opus":0.07661126603921008,"gpt":0.4177776644265036,"spread":0.3411663983872935,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001679827,0.0001113223,0.0005752299,0.0004754348,0.00007225756,0.00004528624,0.00005986904,0.00003170343,0.00001169819],"category_scores_gemma":[0.0008794863,0.00007435231,0.00004746904,0.0002570549,0.0003480686,0.0002702285,0.0000962906,0.0012453,9.263684e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002958042,"about_ca_system_score_gemma":0.0001537175,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000266367,"about_ca_topic_score_gemma":0.000009556879,"domain_scores_codex":[0.9977219,0.0003353144,0.0006450017,0.0002259099,0.0007088241,0.0003630158],"domain_scores_gemma":[0.9987309,0.000401447,0.0001170165,0.0001141087,0.000179249,0.0004572524],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004804207,0.0009714469,0.6246928,0.000176606,0.00003748736,0.01708196,0.0003253224,2.585438e-7,0.2734777,0.00008495612,0.006946145,0.07140114],"study_design_scores_gemma":[0.004229007,0.004006756,0.9823586,0.0003013419,0.00001296711,0.005413142,0.0003153266,0.00005724988,0.000844007,0.001325068,0.001052587,0.00008389907],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9846539,0.01019646,7.738499e-7,0.004324668,0.0000276249,0.0001988827,0.00000122529,0.000004181114,0.0005923227],"genre_scores_gemma":[0.9789407,0.0195905,0.0004688781,0.0001314078,0.0001025724,0.000001449007,0.000001073883,0.000006841237,0.000756565],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3576658,"threshold_uncertainty_score":0.5410277,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2051369708","doi":"10.1097/pai.0b013e3181ad36ea","title":"The Use of Cytokeratin 19 (CK19) Immunohistochemistry in Lesions of the Pancreas, Gastrointestinal Tract, and Liver","year":2009,"lang":"en","type":"review","venue":"Applied immunohistochemistry & molecular morphology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Cytokeratin; Pathology; Immunohistochemistry; Medicine; Pancreas; Neuroendocrine tumors; Gastrointestinal tract; Immunostaining; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.03534072821627239,"gpt":0.3304644647884628,"spread":0.2951237365721904,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002850015,0.0007387318,0.002132864,0.0001306841,0.0001794423,0.00002604555,0.0009018499,0.0001409716,0.00003868604],"category_scores_gemma":[0.001201377,0.000512123,0.0006193703,0.0005199593,0.001789881,0.000038248,0.0004892023,0.002006205,0.000004190994],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003435831,"about_ca_system_score_gemma":0.000961602,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001425628,"about_ca_topic_score_gemma":3.231101e-7,"domain_scores_codex":[0.9960911,0.0002538608,0.001538623,0.0008099241,0.0005601218,0.0007464109],"domain_scores_gemma":[0.9956743,0.0008017256,0.001133747,0.002032127,0.0001737035,0.0001843791],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002371444,0.0003313607,0.00001690405,0.00479796,0.00008457875,0.001703715,0.00001218596,0.000003635253,0.9453259,0.0001001495,0.0004586089,0.0469279],"study_design_scores_gemma":[0.007587619,0.001480371,0.001095473,0.03651381,0.004586558,0.2209866,0.0002439199,0.00002559615,0.2929383,0.0002973818,0.4314625,0.002781897],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.04595512,0.9513742,0.00002417166,0.0001283016,0.00004419986,0.001716258,0.00007654496,0.00002862238,0.0006525527],"genre_scores_gemma":[0.0273322,0.9688004,0.002068337,0.0001400247,0.00004197578,0.0004306101,0.0001680899,0.0001291461,0.0008892734],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.6523876,"threshold_uncertainty_score":0.999733,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2074971086","doi":"10.1097/01.pas.0000213319.04919.97","title":"Nonsmall Cell Lung Carcinoma With Neuroendocrine Differentiation—An Entity of No Clinical or Prognostic Significance","year":2006,"lang":"en","type":"article","venue":"The American Journal of Surgical Pathology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; Vancouver General Hospital","funders":"","keywords":"Chromogranin A; Neuroendocrine differentiation; Synaptophysin; Adenocarcinoma; Tissue microarray; Pathology; Large cell; Carcinoma; Carcinosarcoma; Immunohistochemistry; Small-cell carcinoma; Clinical significance; Medicine; Small Cell Lung Carcinoma; Oncology; Internal medicine; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.02180846643708823,"gpt":0.3278603411464722,"spread":0.306051874709384,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004332802,0.0002126065,0.001005782,0.0001601532,0.00006759637,0.00001425174,0.0003888284,0.000007869821,0.0001260572],"category_scores_gemma":[0.0003152466,0.0001090302,0.0002133504,0.0004221018,0.001554286,0.0001192747,0.00008465776,0.0007929232,0.000009525431],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003111003,"about_ca_system_score_gemma":0.0002704749,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006054069,"about_ca_topic_score_gemma":0.00001974212,"domain_scores_codex":[0.9965613,0.001067811,0.001018897,0.0002956842,0.0005819226,0.00047431],"domain_scores_gemma":[0.9962546,0.001323797,0.00117039,0.0004267342,0.0005502594,0.0002742057],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01275302,0.001847738,0.9140122,0.0000976423,0.00004858203,0.06182195,0.00001913678,0.00006926553,0.007417749,0.00006914086,0.0002921641,0.001551451],"study_design_scores_gemma":[0.005692431,0.02539024,0.9100967,0.00006705092,0.0003315663,0.05254355,0.0001338217,0.0002042973,0.003604973,0.00008729337,0.001655885,0.0001922074],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972965,0.0001542751,0.0002260755,0.001365348,0.0001298306,0.0003690985,0.00000981795,0.00001715114,0.0004319715],"genre_scores_gemma":[0.9974055,0.0002349556,0.001356425,0.0001414657,0.0004162599,0.000009654659,0.000004632407,0.00003244873,0.0003986835],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0235425,"threshold_uncertainty_score":0.5726833,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1966261847","doi":"10.1097/igc.0000000000000262","title":"Gynecologic Cancer InterGroup (GCIG) Consensus Review for Small Cell Carcinoma of the Cervix","year":2014,"lang":"en","type":"review","venue":"International Journal of Gynecological Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Cervix; Adenocarcinoma; Incidence (geometry); Stage (stratigraphy); Cervical cancer; Cancer; Carcinoma; Metastasis; Oncology; Epidemiology; Uterine cervix; Basal cell; Gynecology; Pathology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.09253205530852371,"gpt":0.4287712521355705,"spread":0.3362391968270468,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00074122,0.0004985782,0.003012324,0.0002557403,0.00005768378,0.00002661341,0.001733941,0.000111274,0.001870705],"category_scores_gemma":[0.004470982,0.0002608904,0.002118602,0.000286995,0.0003337008,0.00004686519,0.0004184541,0.001216558,0.000009436026],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009935122,"about_ca_system_score_gemma":0.001813368,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004472672,"about_ca_topic_score_gemma":0.0001213849,"domain_scores_codex":[0.9954509,0.0004896685,0.002127819,0.0004339895,0.001015639,0.0004820155],"domain_scores_gemma":[0.990778,0.00307929,0.003229351,0.0003892596,0.002270247,0.0002539059],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004933777,0.0007264463,0.00217298,0.06941354,0.001208732,0.001351325,0.00001244088,0.00001975519,0.00003621752,0.0001674814,0.04079273,0.883605],"study_design_scores_gemma":[0.001423618,0.001197556,0.0006716169,0.02736995,0.001636952,0.001330603,0.000008058426,0.000006327979,0.0001034865,0.0001287106,0.9658923,0.0002308059],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001477122,0.9875851,0.00002085294,0.004511937,0.003450033,0.002059649,0.0002687463,0.00001137315,0.0006151801],"genre_scores_gemma":[0.004505626,0.9898104,0.000378068,0.002342033,0.0009821336,0.0004800398,0.00001366794,0.00005645895,0.001431544],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9250996,"threshold_uncertainty_score":0.9999843,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3156669433","doi":"10.1136/gutjnl-2020-322595","title":"Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size","year":2021,"lang":"en","type":"article","venue":"Gut","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Hospital Foundation","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; North American Neuroendocrine Tumor Society; Neuroendocrine Tumor Research Foundation; National Research Foundation of Korea; Ministero della Salute; National Cancer Institute; National Research Foundation; Maag Lever Darm Stichting; Associazione Italiana per la Ricerca sul Cancro; University of Pittsburgh; National Institutes of Health; Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona","keywords":"ATRX; Death-associated protein 6; PDX1; Neuroendocrine tumors; Biology; Cancer research; Internal medicine; Oncology; Pathology; Medicine; Endocrinology; Gene; Nuclear protein; Transcription factor; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.01996106860374286,"gpt":0.2827170306533476,"spread":0.2627559620496048,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007389066,0.0002648917,0.0005538947,0.000111363,0.0001003347,0.0000485263,0.0001031483,0.00001154674,0.0001870283],"category_scores_gemma":[0.002561866,0.0002227638,0.0000701813,0.0001684224,0.0002148762,0.0002093779,0.0003590647,0.0004652768,0.00001010048],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003312903,"about_ca_system_score_gemma":0.0001407211,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000109477,"about_ca_topic_score_gemma":0.00003307005,"domain_scores_codex":[0.9976481,0.0001284708,0.0004084697,0.0006395393,0.0007483613,0.0004270897],"domain_scores_gemma":[0.997871,0.001089162,0.0001928819,0.0002898317,0.0002220041,0.0003351469],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.0008311694,0.0003066284,0.4133792,0.0003073163,0.0001020564,0.01201605,0.0001724265,0.0000180935,0.5713567,0.00006416377,0.0002544856,0.00119171],"study_design_scores_gemma":[0.002924441,0.000466104,0.7116305,0.0008266099,0.0001118981,0.002265378,0.0007504318,0.0002689981,0.2796303,0.0006548917,0.0002892991,0.0001811039],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961761,0.001109472,0.0000699278,0.001642201,0.000124342,0.0004632685,0.00005429855,0.00004585653,0.0003145842],"genre_scores_gemma":[0.9963354,0.0005845777,0.001997832,0.0001903476,0.0002454238,0.00005378592,0.00003092042,0.0000434977,0.0005182549],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2982514,"threshold_uncertainty_score":0.9084046,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3016349309","doi":"10.1002/cncr.32883","title":"Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study","year":2020,"lang":"en","type":"article","venue":"Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pharmacyclics; Chugai Pharmaceutical; Merck Sharp and Dohme; EMD Serono; Genentech; Bavarian Nordic; Sirtex Medical; FibroGen; Eisai; Celgene; Rakuten Medical; Aminex Therapeutics; Pfizer; Incyte; Ipsen; Five Prime Therapeutics; Les Laboratories Pierre Fabre; MacroGenics; Celldex Therapeutics; Principia Biopharma; Puma Biotechnology; National Institutes of Health; Regeneron Pharmaceuticals; BioMarin Pharmaceutical; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; Alexion Pharmaceuticals; Halozyme; Kyowa Hakko Kirin; Sanofi; GlaxoSmithKline; Amgen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Cohort; Internal medicine; Neuroendocrine tumors; Clinical endpoint; Gastroenterology; Response Evaluation Criteria in Solid Tumors; Oncology; Progressive disease; Immunotherapy; Cancer; Disease; Clinical trial","retraction":null,"screen_n_in":null,"score":{"opus":0.07047732118771373,"gpt":0.3677005988134592,"spread":0.2972232776257455,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005702347,0.0003613497,0.0007060462,0.00003634653,0.0002048866,0.00003842985,0.0003476857,0.000006699363,0.00004057714],"category_scores_gemma":[0.001012369,0.0001692795,0.000202075,0.0003954112,0.0002006634,0.00009116217,0.00007745822,0.0002147395,0.000005498484],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001755444,"about_ca_system_score_gemma":0.0003536593,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001613925,"about_ca_topic_score_gemma":0.0005720506,"domain_scores_codex":[0.9974545,0.0001562936,0.00054875,0.0006837294,0.0005450165,0.0006117492],"domain_scores_gemma":[0.9965478,0.001962349,0.0002307619,0.0007241601,0.0002664076,0.0002685771],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.4425594,0.009117593,0.1614041,0.0009167324,0.004940362,0.01862326,0.03048863,0.001533307,0.03443279,0.0001000649,0.008283416,0.2876003],"study_design_scores_gemma":[0.1297245,0.09047844,0.3053923,0.0007081115,0.003939258,0.0005226309,0.01498581,0.003185305,0.337923,0.0001321507,0.1120594,0.0009491202],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9689642,0.003722918,0.00002654073,0.01779776,0.0001361707,0.008420447,0.0007771822,0.00008058982,0.00007416384],"genre_scores_gemma":[0.9929873,0.00161779,0.0001738133,0.0009146942,0.0005566736,0.002821565,0.00005962009,0.00007105044,0.000797449],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3128349,"threshold_uncertainty_score":0.6903018,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2168006827","doi":"10.1016/j.surg.2008.06.008","title":"The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors","year":2008,"lang":"en","type":"article","venue":"Surgery","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Carcinoid syndrome; Neuroendocrine tumors; Surgery; Gastrointestinal tract; Metastasis; Palliative care; Ischemia; Internal medicine; Gastroenterology; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.03969982662727681,"gpt":0.3303852181001614,"spread":0.2906853914728846,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001294473,0.0001649017,0.000517958,0.0001220079,0.0001430297,0.00001357209,0.00008255008,0.000003907862,0.00004486999],"category_scores_gemma":[0.001839856,0.0001084396,0.0002737011,0.0001834964,0.0003186815,0.0001035978,0.00009153518,0.000135197,0.000002568853],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002142662,"about_ca_system_score_gemma":0.00005266913,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000199088,"about_ca_topic_score_gemma":0.00004588722,"domain_scores_codex":[0.9984039,0.0001382857,0.0004671373,0.0002857658,0.0003514039,0.0003535011],"domain_scores_gemma":[0.9954153,0.003622332,0.0004346293,0.0002500085,0.0001344167,0.0001433471],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007942084,0.00102536,0.903075,0.0008629744,0.0007549453,0.03763527,0.0001648777,0.00001206843,0.002323235,0.000428101,0.007675981,0.03810014],"study_design_scores_gemma":[0.01155586,0.003121458,0.788142,0.00252602,0.0005386605,0.01487857,0.001036376,0.001274162,0.1328127,0.004913906,0.03837257,0.0008276964],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937658,0.004403111,0.00002461406,0.0009456113,0.0001465156,0.0005148711,0.0001321271,0.00002917345,0.00003811811],"genre_scores_gemma":[0.9955065,0.003549939,0.0001328613,0.00004497436,0.00008143025,0.0001149047,0.00007227377,0.00002668002,0.0004704194],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1304895,"threshold_uncertainty_score":0.442204,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2604953360","doi":"10.1097/pas.0000000000000801","title":"Uterine Inflammatory Myofibroblastic Tumors Frequently Harbor ALK Fusions With IGFBP5 and THBS1","year":2017,"lang":"en","type":"article","venue":"The American Journal of Surgical Pathology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Vancouver General Hospital; BC Cancer Agency; University of Alberta","funders":"","keywords":"Anaplastic lymphoma kinase; Fluorescence in situ hybridization; Pathology; ROS1; Leiomyoma; Fusion gene; Smooth Muscle Tumor; Differential diagnosis; Immunohistochemistry; Gene rearrangement; Biology; Medicine; Gene; Adenocarcinoma; Genetics; Cancer; Chromosome","retraction":null,"screen_n_in":null,"score":{"opus":0.01452964031700409,"gpt":0.3144245204075089,"spread":0.2998948800905048,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0003535304,0.0001790937,0.0006637521,0.0001358857,0.0002684778,0.00004338687,0.0003916384,0.000007595141,0.00007762625],"category_scores_gemma":[0.000331113,0.00009292222,0.00009477982,0.00009179379,0.002901791,0.0001622341,0.0002120136,0.000631622,0.0000115724],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002539827,"about_ca_system_score_gemma":0.0001361032,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000163563,"about_ca_topic_score_gemma":0.00000581322,"domain_scores_codex":[0.998389,0.0002374671,0.0003882168,0.000195639,0.0003843051,0.0004053542],"domain_scores_gemma":[0.9977576,0.0003883044,0.0007719304,0.0005294667,0.0001803614,0.0003723238],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"case_report","study_design_gemma":"observational","study_design_scores_codex":[0.01741944,0.000524686,0.206607,0.0001790533,0.0003930568,0.647374,0.0003414901,0.00005602429,0.08527312,0.00236752,0.0005554428,0.03890924],"study_design_scores_gemma":[0.005153348,0.01259675,0.6671667,0.0003580532,0.0001466705,0.2956642,0.0004140736,0.00004282215,0.001745914,0.0006639427,0.01578097,0.0002666552],"study_design_candidate":"case_report","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9876531,0.0001983061,0.00005249378,0.01108025,0.00006412071,0.0001526461,0.000005192225,0.00001503186,0.0007788592],"genre_scores_gemma":[0.9977397,0.0007146437,0.0008244186,0.0002730193,0.0002287788,0.000005724386,3.8623e-7,0.00002652579,0.0001867924],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4605597,"threshold_uncertainty_score":0.9998118,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2149569966","doi":"10.1189/jlb.0606417","title":"Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages","year":2006,"lang":"en","type":"article","venue":"Journal of Leukocyte Biology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Università di Pisa; Western University; Università degli Studi della Tuscia","keywords":"Somatostatin; Biology; Somatostatin receptor; Receptor; Endocrinology; Internalization; Internal medicine; Somatostatin receptor 2; Antagonist; Secretion; Biochemistry; Medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.01217889586053243,"gpt":0.3199127617431584,"spread":0.307733865882626,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000160698,0.00008494806,0.0003124628,0.0002411458,0.00003077892,0.000003829429,0.00004432688,0.00001866605,0.0001519015],"category_scores_gemma":[0.00007510346,0.00006203807,0.00003124315,0.00007261011,0.0002589246,0.00007361506,0.0000474277,0.0002340481,9.125141e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002633055,"about_ca_system_score_gemma":0.00006571077,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003012611,"about_ca_topic_score_gemma":0.00001103956,"domain_scores_codex":[0.9991008,0.0001218849,0.0003877258,0.0001173855,0.0001020356,0.0001701659],"domain_scores_gemma":[0.9993631,0.0001606535,0.0002386768,0.00004705101,0.0001139838,0.00007651396],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0007306898,0.00008428864,0.172545,0.00003443177,0.00001398205,0.0001717412,0.00001337966,0.00000405374,0.8245075,0.00006833787,0.001442039,0.0003844978],"study_design_scores_gemma":[0.003097834,0.0009529623,0.1864009,0.000053121,0.00001803443,0.001849329,0.0001316903,0.000008039355,0.7998413,0.00119193,0.006400187,0.00005468016],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993627,0.005524153,0.000005803568,0.0005296315,0.00008525004,0.00009329077,0.000005214156,0.000004211545,0.0001254303],"genre_scores_gemma":[0.9982976,0.0005345985,0.0007661939,0.00005997989,0.0001981717,0.000002756755,0.000004542397,0.000007923264,0.0001281857],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02466623,"threshold_uncertainty_score":0.2529839,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2059578957","doi":"10.1046/j.1365-2265.2001.01175.x","title":"Immunohistochemical detection of somatostatin receptor types 1–5 in medullary carcinoma of the thyroid","year":2001,"lang":"en","type":"article","venue":"Clinical Endocrinology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"National Institute of Neurological Disorders and Stroke; Medical Research Council; Ministero dell'Università e della Ricerca","keywords":"Somatostatin; Somatostatin receptor; Immunohistochemistry; Internal medicine; Endocrinology; Biology; Thyroid carcinoma; Pathology; Autocrine signalling; Thyroid; Medullary carcinoma; Somatostatin receptor 2; Receptor; Medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.03347757272442397,"gpt":0.3660263914831249,"spread":0.332548818758701,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001623364,0.0001183178,0.000530173,0.0001187226,0.00002215825,0.000001285575,0.0002554605,0.00003409938,0.0001079406],"category_scores_gemma":[0.002994361,0.00008481153,0.0001866684,0.0003363605,0.0007743518,0.000035663,0.000192271,0.0006268848,0.00002077025],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000436553,"about_ca_system_score_gemma":0.0001349969,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001066744,"about_ca_topic_score_gemma":0.00004471782,"domain_scores_codex":[0.9979405,0.0003096183,0.0008692252,0.0002789099,0.000231007,0.0003707224],"domain_scores_gemma":[0.9983512,0.0007597974,0.000219518,0.0004660301,0.0001224802,0.00008096497],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001669975,0.0005928092,0.489929,0.00009877099,0.00003983102,0.0004108131,0.00003089135,0.000002846773,0.4919966,0.0003042181,0.0002491904,0.01467515],"study_design_scores_gemma":[0.004349281,0.002055735,0.3855006,0.00009029089,0.00004147871,0.001954857,0.0001564977,0.0000532281,0.5971082,0.0007012283,0.007862547,0.0001259729],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954964,0.001026782,0.00001043252,0.001677136,0.000322422,0.0003613593,0.000004742787,0.00002010829,0.001080642],"genre_scores_gemma":[0.9984972,0.0006181804,0.0003186693,0.0001629009,0.00006926813,0.00002260744,0.000003237176,0.00001691302,0.0002909489],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1051117,"threshold_uncertainty_score":0.3584746,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2605007480","doi":"10.1503/cmaj.160771","title":"Principles of diagnosis and management of neuroendocrine tumours","year":2017,"lang":"en","type":"review","venue":"Canadian Medical Association Journal","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Diarrhea; Neuroendocrine tumour; Neuroendocrine tumors; Population; Medicine; Computer science; Internal medicine; Bioinformatics; Pathology; Intensive care medicine; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.07402426020434809,"gpt":0.3861827877637625,"spread":0.3121585275594144,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007433353,0.0002434343,0.001609493,0.0005197853,0.0001286287,0.00003875403,0.0004258624,0.00005097105,0.0005462311],"category_scores_gemma":[0.00306356,0.0001959134,0.000344777,0.0001800921,0.0001527893,0.00008316113,0.0001087674,0.001211051,0.00001254142],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004466035,"about_ca_system_score_gemma":0.002737672,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004472157,"about_ca_topic_score_gemma":0.001754337,"domain_scores_codex":[0.9961119,0.0002313286,0.001065104,0.0002422409,0.00180995,0.0005395109],"domain_scores_gemma":[0.9958929,0.0003143364,0.001371799,0.0003046123,0.0003224668,0.001793932],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000005858081,0.00005255258,0.007059737,0.01330174,0.0004652254,0.02030767,0.000005028257,7.652905e-8,2.353687e-8,0.0002880284,0.004398493,0.9541156],"study_design_scores_gemma":[0.000556658,0.0001476193,0.001921079,0.01643494,0.000573659,0.006893568,0.00002047315,0.00000138109,0.000002043562,0.00001002717,0.9733312,0.0001073489],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002778831,0.9910018,6.111587e-7,0.003532573,0.0003262822,0.0006528127,0.00008725568,0.000006880696,0.004113845],"genre_scores_gemma":[0.0001726093,0.9975563,0.0001179292,0.000141371,0.000324549,0.0000427431,0.00001331221,0.00003710647,0.001594095],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9689327,"threshold_uncertainty_score":0.7989115,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1968704126","doi":"10.1159/000369071","title":"Mixed Adenoneuroendocrine Carcinomas of the Gastrointestinal Tract: Targeted Next-Generation Sequencing Suggests a Monoclonal Origin of the Two Components","year":2014,"lang":"en","type":"article","venue":"Neuroendocrinology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Hospital Foundation","funders":"","keywords":"KRAS; Sanger sequencing; Biology; Gastrointestinal tract; Mutation; Adenocarcinoma; Somatic cell; Neuroendocrine tumors; Germline mutation; Cancer; Neoplastic transformation; Cancer research; Pathology; Gene; Carcinogenesis; Genetics; Medicine; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.09713277816815528,"gpt":0.3058181493632691,"spread":0.2086853711951138,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00004818848,0.0004045997,0.0007295731,0.0002416496,0.0001968608,0.00001859894,0.0008253433,0.00001001308,0.00007035637],"category_scores_gemma":[0.001444957,0.0002671993,0.0003432831,0.0006039568,0.0007789562,0.0001608854,0.0004843807,0.001001822,0.0000146204],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000114426,"about_ca_system_score_gemma":0.0002976077,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003744042,"about_ca_topic_score_gemma":0.0001865107,"domain_scores_codex":[0.9956792,0.0009271367,0.000891702,0.0006599881,0.0008787722,0.0009631737],"domain_scores_gemma":[0.9972242,0.0004191463,0.0005643015,0.001215755,0.0003755737,0.000201085],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.0002093342,0.0002071269,0.3079378,0.0001137101,0.00001429946,0.0006694866,0.00001702948,0.0003682915,0.6887611,0.0008252339,0.0003995566,0.0004770871],"study_design_scores_gemma":[0.003186912,0.001125374,0.5155701,0.0001207161,0.0001080837,0.03470815,0.0000355736,0.005152099,0.4373805,0.0001172195,0.002325719,0.0001695441],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928631,0.0001471196,0.00004314154,0.00474217,0.0007770903,0.0009603211,0.00003478544,0.00007125992,0.0003610741],"genre_scores_gemma":[0.9978213,0.00005465978,0.0008472406,0.0005040184,0.0002420933,0.00004729697,0.00002029112,0.00006655871,0.0003965974],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2513806,"threshold_uncertainty_score":0.999978,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W116293535","doi":"10.1016/j.cellsig.2007.07.007","title":"Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2","year":2007,"lang":"en","type":"article","venue":"Cellular Signalling","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Royal Victoria Hospital; University of British Columbia; McGill University","funders":"","keywords":"HEK 293 cells; Internalization; Agonist; Receptor; Somatostatin receptor; Cell biology; Eticlopride; Transfection; Somatostatin; Chemistry; Somatostatin receptor 2; Dopamine receptor D2; G protein-coupled receptor; Dopamine receptor; Endogenous agonist; Dopamine; Chinese hamster ovary cell; Biology; Biochemistry; Dopamine receptor D1; Endocrinology; SCH-23390","retraction":null,"screen_n_in":null,"score":{"opus":0.01986217199746808,"gpt":0.3003465407933429,"spread":0.2804843687958748,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002907559,0.000137365,0.00027564,0.000200273,0.00007664217,0.00001387003,0.00007396092,0.00001437464,0.0002328723],"category_scores_gemma":[0.0001421668,0.0001302435,0.00005032549,0.0002299188,0.0001227895,0.00009625816,0.00004528541,0.0001706654,0.00001929981],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002697431,"about_ca_system_score_gemma":0.00002241172,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001188434,"about_ca_topic_score_gemma":0.000002736326,"domain_scores_codex":[0.998632,0.00004100127,0.0003953128,0.0002602805,0.0003467577,0.0003246479],"domain_scores_gemma":[0.9992684,0.0001109567,0.0001364022,0.0001683047,0.0001245104,0.0001914298],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001104566,0.00007446166,0.005016903,0.0002333312,0.00001901539,0.0001398727,0.00008535542,0.000005929516,0.9922217,0.0001620153,0.00003823324,0.001892697],"study_design_scores_gemma":[0.0008379004,0.0005232207,0.0003725729,0.0001455617,0.00001709162,0.00004402303,0.0001887143,0.00009109775,0.9958422,0.00006077821,0.001770353,0.0001064593],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920948,0.0007304631,0.006082901,0.0001010453,0.0000662551,0.0003392186,0.00000475867,0.00005517721,0.0005254447],"genre_scores_gemma":[0.9940604,0.0001023651,0.004940739,0.00003964545,0.0001328807,0.00000542031,0.00008029405,0.00003710435,0.0006011564],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00464433,"threshold_uncertainty_score":0.5311176,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}